

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
20 September 2001 (20.09.2001)

PCT

(10) International Publication Number
WO 01/68864 A1

- (51) International Patent Classification⁷: **C12N 15/31, 15/67 // (C12N 15/31, C12R 1:69)**
- (21) International Application Number: **PCT/DK01/00169**
- (22) International Filing Date: **14 March 2001 (14.03.2001)**
- (25) Filing Language: **English**
- (26) Publication Language: **English**
- (30) Priority Data:
PA 2000 00406 14 March 2000 (14.03.2000) DK
- (71) Applicant: **NOVOZYMES A/S [DK/DK]**; Krogshøjvej 36, DK-2880 Bagsværd (DK).
- (72) Inventors: **HJORT, Carsten, M.; Råbroparken 36, DK-2765 Smørum (DK). HONDEL, C., MJ van den; Waterlelie 124, NL-2804 PZ Gouda (NL). PUNT, P., J.; Boekdukkersgilde, NL-3994 XT Houten (NL). SCHUREN, F., H., J.; Bachlaan 34, NL-3906 ZK Veenendaal (NL). CHRISTENSEN, Tove; Nøddevænget 3, DK-2800 Lyngby (DK).**
- (81) Designated States (national): **AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,**
- (84) Designated States (regional): **ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).**

Published:

- *with international search report*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*
- *with (an) indication(s) in relation to deposited biological material furnished under Rule 13bis separately from the description*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 01/68864 A1

(54) Title: **FUNGAL TRANSCRIPTIONAL ACTIVATOR USEFUL IN METHODS FOR PRODUCING POLYPEPTIDES**

(57) Abstract: The present invention relates to isolated nucleic acid sequences encoding polypeptides having transcriptional activation activity and to the polypeptides. The invention also relates to nucleic acid constructs, vectors and host cells comprising the nucleic acid sequences. The invention further relates to host cells useful for the production of polypeptides in which the production or function of the transcriptional activator has been altered, as well as to methods for producing the polypeptides.

**FUNGAL TRANSCRIPTIONAL ACTIVATOR USEFUL IN METHODS
FOR PRODUCING POLYPEPTIDES**

Background of the Invention

5

Field of the Invention

The present invention relates to isolated nucleic acid sequences encoding polypeptides having transcriptional activation activity and to the polypeptides. The invention also 10 relates to nucleic acid constructs, vectors and host cells comprising the nucleic acid sequences. The invention further relates to host cells useful for the production of polypeptides in which the production or function of the transcriptional activator has been altered, as well as to methods for producing 15 the polypeptides.

Description of the Related Art

The use of recombinant host cells in the expression of heterologous proteins has in recent years greatly simplified the 20 production of large quantities of commercially valuable proteins which otherwise are obtainable only by purification from their native sources. Currently, there is a varied selection of expression systems from which to choose for the production of any given protein, including eubacterial and eukaryotic hosts. 25 The selection of an appropriate expression system often depends not only on the ability of the host cell to produce adequate yields of the protein in an active state, but, to a large extent, may also be governed by the intended end use of the protein.

30 One problem frequently encountered is the high level of proteolytic enzymes produced by a given host cell or present in the culture medium. One suggestion has been to provide host organisms deprived of the ability to produce specific proteolytic compounds. For example, WO 90/00192 (Genencor,

Inc.) describes filamentous fungal hosts incapable of secreting enzymatically active aspartic proteinase. EP 574 347 (Ciba Geigy AG) describes *Aspergillus* hosts defective in a serine protease of the subtilisin-type. WO 98/12300 (Novo Nordisk A/S) 5 describes hosts defective in a metalloprotease and an alkaline protease. WO 97/12045 (Genencor, Inc.) describes yeast and bacterial host systems, which are rendered protease deficient resulting from a disruption of a promoter sequence involved in the regulation of a protease gene.

10 Mattern, I.E., et al., (1992. Mol Gen Genet 234:332-336) describe a mutant strain of *Aspergillus niger*, which was shown to have only 1 to 2% of the extracellular protease activity of the parent strain, apparently due to a deficiency of at least two proteases, aspergillopepsin A and aspergillopepsin B. It 15 was suggested that the protease deficient phenotype could result from a regulatory mutation affecting the expression of the genes coding for both proteases.

The initiation of eukaryotic transcription at a specific promoter or set of promoters requires a eukaryotic 20 transcriptional activator which is a polypeptide, but which is not itself part of RNA polymerase. Many transcriptional activators bind to a specific site on the promoter to form a functional promoter necessary for the initiation of transcription of the polypeptide encoding sequence. However, a 25 transcriptional activator may also be incorporated into an initiation complex only in the presence of other polypeptides. Polypeptides with transcriptional activation activity have been described in fungi, and a list of such polypeptides has been published (Dhawale, S.S., and Lane, A.C. 1993. Nucleic Acid 30 Research 21:5537-5546).

Solution proposed by the invention:

It is an object of the present invention to provide improved methods for increasing production of polypeptides in host cells

in which the activity of a transcriptional activator involved in the regulation of protease production has been modified.

Summary of the Invention

- 5 A first aspect of the present invention relates to an isolated nucleic acid sequence encoding a transcriptional activator selected from the group consisting of:
- 10 (a) a nucleic acid sequence having at least 70% identity with the nucleic acid sequence of SEQ ID NO:1 or SEQ ID NO: 48;
- (b) a nucleic acid sequence encoding a polypeptide having an amino acid sequence which has at least 50% identity with the amino acid sequence of SEQ ID NO:2 or SEQ ID NO: 49;
- 15 (c) a nucleic acid sequence which hybridizes under low stringency conditions with (i) the nucleic acid sequence of SEQ ID NO:1 or SEQ ID NO: 48, or (ii) its complementary strand, wherein the low stringency conditions are defined by prehybridization and hybridization at 42°C in 5x SSPE, 0.3% SDS, 200 microg/ml sheared and denatured salmon sperm DNA, and 25% formamide, and wash conditions are defined by 50°C for 30 minutes in 2X SSC, 0.2% SDS;
- 20 (d) an allelic variant of (a), (b), or (c);
- 25 (e) a subsequence of (a), (b), (c), or (d), wherein the subsequence encodes a polypeptide fragment which has transcriptional activation activity; and
- (f) a subsequence of (a), (b) (c), or (d), wherein the subsequence encodes a polypeptide with the amino acid sequence of SEQ ID NO:3.

The nucleic acid sequence shown in SEQ ID NO: 1 is the *Aspergillus niger prtT* gene encoding the transcriptional factor

shown in SEQ ID NO: 2 as described further below and in the Examples.

The nucleic acid sequence shown in SEQ ID NO: 48 is the *Aspergillus oryzae* IFO4177 *prtT* gene encoding the 5 transcriptional factor shown in SEQ ID NO: 49. The *A. oryzae* *prtT* gene has a coding region starting in position 795 and ending at position 2931. The *prtT* gene has 4 introns in positions 1028-1135, 1538-1591, 2018-2066, and 2297-2347, respectively. This is described further below and in the 10 Examples.

In another aspect, the invention also relates to nucleic acid constructs, vectors and host cells comprising the nucleic acid sequences, and to the polypeptides encoded by the nucleic acid sequences. The invention further relates to host cells 15 useful for the production of a polypeptide, in which the production or function of the transcriptional activator has been altered, as well as to methods for producing the polypeptide.

20 Brief Description of the Figures

Figure 1 shows a restriction map of the plasmid pPAP, the construction of which is described in Example 1.

Figure 2 shows a restriction map of the plasmid pAopyrGcosArp1, the construction of which is described in 25 Example 1.

Figure 3 shows a restriction map of the plasmid pEES1, the construction of which is described in Example 1.

Figure 4 shows a restriction map of the plasmid pDprt, the construction of which is described in Example 3.

30 Figure 5 shows a restriction map of the plasmid pGPprt, the construction of which is described in Example 4.

Figure 6 shows the sequence of the insert in the two plasmids containing the PCR fragment of the *A. oryzae* *prtT* Zn²⁺-

finger. ICA217 is the sequence from one of the plasmids and ICA218 is the sequence from the other.

Figure 7 shows plasmid pDV8 a pSP65 (Promega™) based plasmid containing the HSV-tk gene on a 1.2 kb *BglII/BamHI* fragment inserted between a 1.0 kb *XhoI/BglII* fragment of the *A. nidulans* *gpd* promoter and a 0.8 kb *BamHI/HindIII* fragment containing the *A. nidulans* *trpC* transcriptional terminator.

Figure 8 shows the construction of pJaL554 described in Example 8.

10

Detailed Description of the Invention

Nucleic Acid Sequences Encoding Transcriptional Activators

A first aspect of the present invention relates to an 15 isolated nucleic acid sequence encoding a transcriptional activator selected from the group consisting of:

- (a) a nucleic acid sequence having at least 70% identity with the nucleic acid sequence of SEQ ID NO:1 or SEQ ID NO: 48;
- 20 (b) a nucleic acid sequence encoding a polypeptide having an amino acid sequence which has at least 50% identity with the amino acid sequence of SEQ ID NO:2 or SEQ ID NO: 49;
- 25 (c) a nucleic acid sequence which hybridizes under low stringency conditions with (i) the nucleic acid sequence of SEQ ID NO:1 or SEQ ID NO: 48, or (ii) its complementary strand, wherein the low stringency conditions are defined by prehybridization and hybridization at 42°C in 5x SSPE, 0.3% SDS, 200 micro g/ml sheared and denatured salmon sperm DNA, and 25% formamide, and wash conditions are defined by 50°C for 30 minutes in 2X SSC, 0.2% SDS;
- 30 (d) an allelic variant of (a), (b), or (c);

- (e) a subsequence of (a), (b), (c), or (d), wherein the subsequence encodes a polypeptide fragment which has transcriptional activation activity; and
- 5 (f) a subsequence of (a), (b), (c), or (d), wherein the subsequence encodes a polypeptide with the amino acid sequence of SEQ ID NO:3.

The term "transcriptional activator" as used herein refers to a polypeptide which has the capability to activate a specific promoter or set of promoters necessary for the 10 initiation of transcription of the polypeptide encoding sequence to which it is linked.

The term "isolated nucleic acid sequence" as used herein refers to a nucleic acid sequence which is essentially free of other nucleic acid sequences, e.g., at least about 20% pure, 15 preferably at least about 40% pure, more preferably at least about 60% pure, even more preferably at least about 80% pure, most preferably at least about 90% pure as determined by agarose electrophoresis. For example, an isolated nucleic acid sequence can be obtained by standard cloning procedures used in 20 genetic engineering to relocate the nucleic acid sequence from its natural location to a different site where it will be reproduced. The cloning procedures may involve excision and isolation of a desired nucleic acid fragment comprising the nucleic acid sequence encoding the polypeptide, insertion of 25 the fragment into a vector molecule, and incorporation of the recombinant vector into a host cell where multiple copies or clones of the nucleic acid sequence will be replicated. The nucleic acid sequence may be of genomic, cDNA, RNA, semisynthetic, synthetic origin, or any combinations thereof.

30 In a preferred embodiment, the nucleic acid sequence has a degree of identity to the nucleic acid sequence set forth in SEQ ID NO:1 or SEQ ID NO: 48 of at least about 70%, preferably at least about 80%, more preferably at least about 85%, even more preferably at least about 90%, most preferably at least

about 95%, even most preferably at least about 97%, and even more preferred at least 99% identity, which encodes an active polypeptide. For purposes of the present invention, the degree of identity between two nucleic acid sequences is determined by 5 the Clustal method (Higgins, 1989, CABIOS 5:151-153) with an identity table, a gap penalty of 10, and a gap length penalty of 10.

In an even more preferred embodiment, the nucleic acid sequence encoding a transcriptional activator has a nucleic acid sequence as set forth in SEQ ID NO:1 or SEQ ID NO: 48.

Modification of a nucleic acid sequence encoding a polypeptide of the present invention may be necessary for the synthesis of polypeptides substantially similar to the polypeptide. The term "substantially similar" to the polypeptide 15 refers to non-naturally occurring forms of the polypeptide. These polypeptides may differ in some engineered way from the polypeptide isolated from its native source. For example, it may be of interest to synthesize variants of the polypeptide where the variants differ in specific activity, binding 20 specificity and/or affinity, or the like using, e.g., site-directed mutagenesis. The analogous sequence may be constructed on the basis of the nucleic acid sequence presented as the polypeptide encoding part of SEQ ID NO: 1 or SEQ ID NO: 48, e.g., a subsequence thereof, and/or by introduction of 25 nucleotide substitutions which do not give rise to another amino acid sequence of the polypeptide encoded by the nucleic acid sequence, but which corresponds to the codon usage of the host organism intended for production of the enzyme, or by introduction of nucleotide substitutions which may give rise to 30 a different amino acid sequence. For a general description of nucleotide substitution, see, e.g., Ford et al., 1991, *Protein Expression and Purification* 2: 95-107.

In another preferred embodiment, the present invention relates to isolated nucleic acid sequences encoding

polypeptides having an amino acid sequence which has a degree of identity to the amino acid sequence set forth in SEQ ID NO:2 or SEQ ID NO: 49 of at least about 50%, preferably at least about 60%, preferably at least about 70%, more preferably at least about 80%, even more preferably at least about 90%, most preferably at least about 95%, even most preferably at least about 97%, and even more preferred at least 99%, which qualitatively retain the transcriptional activation activity of the polypeptides (hereinafter "homologous polypeptides").

In a preferred embodiment, the homologous polypeptides have an amino acid sequence which differs by five amino acids, preferably by four amino acids, more preferably by three amino acids, even more preferably by two amino acids, and most preferably by one amino acid from the amino acid sequence set forth in SEQ ID NO:2 or SEQ ID NO: 49. For purposes of the present invention, the degree of identity between two amino acid sequences is determined by the Clustal method (Higgins, 1989, *supra*) with an identity table, a gap penalty of 10, and a gap length penalty of 10.

Hybridization indicates that by methods of standard Southern blotting procedures, the nucleic acid sequence hybridizes to an oligonucleotide probe corresponding to the polypeptide encoding part of the nucleic acid sequence shown in SEQ ID NO:1, under low to high stringency conditions (*i.e.*, prehybridization and hybridization at 42°C in 5x SSPE, 0.3% SDS, 200 µg/ml sheared and denatured salmon sperm DNA, and either 25, 35 or 50% formamide for low, medium and high stringencies, respectively). In order to identify a clone or DNA which is homologous with SEQ ID NO:1 or SEQ ID NO: 48, the hybridization reaction is washed three times for 30 minutes each using 2X SSC, 0.2% SDS preferably at least 50°C, more preferably at least 55°C, more preferably at least 60°C, more preferably at least 65°C, even more preferably at least 70°C, and most preferably at least 75°C.

The nucleic acid sequence of SEQ ID NO:1 or SEQ ID NO: 48, or a subsequence thereof, as well as the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 49, or a partial sequence thereof, or the amino acid sequence of SEQ ID NO:3, may be used to 5 design an oligonucleotide probe to identify and isolate or clone a homologous gene of any genus or species according to methods well known in the art.

In particular, such probes can be used for hybridization with the genomic or cDNA of the genus or species of interest, 10 following standard Southern blotting procedures, in order to identify and isolate the corresponding gene therein. Such probes can be considerably shorter than the entire sequence, but should be at least 15, preferably at least 25, and more preferably at least 40 nucleotides in length. Longer probes 15 can also be used. Both DNA and RNA probes can be used. The probes are typically labeled for detecting the corresponding gene (for example, with ^{32}P , ^3H , ^{35}S , biotin, or avidin). For example, molecules to which a ^{32}P -, ^3H - or ^{35}S -labelled oligonucleotide probe hybridizes may be detected by use of X- 20 ray film.

Thus, a genomic, cDNA or combinatorial chemical library prepared from such other organisms may be screened for DNA which hybridizes with the probes described above and which encodes a polypeptide with transcriptional activation activity. 25 Genomic or other DNA from such other organisms may be separated by agarose or polyacrylamide gel electrophoresis, or other separation techniques. DNA from the libraries or the separated DNA may be transferred to and immobilized on nitrocellulose or other suitable carrier material. A clone or DNA which is 30 homologous to SEQ ID NO:1 or SEQ ID NO: 48 may then be identified following standard Southern blotting procedures.

An allelic variant denotes any of two or more alternative forms of a gene occupying the same chromosomal locus. Allelic variation arises naturally through mutation, and may result in

phenotypic polymorphism within populations. Gene mutations can be silent (i.e., no change in the encoded polypeptide) or may encode polypeptides having altered amino acid sequences.

The term "allelic variant of a polypeptide" is a polypeptide 5 encoded by an allelic variant of a gene. In a preferred embodiment, the nucleic acid sequence encoding a transcriptional activator of the present invention is an allelic variant of a nucleic acid sequence selected from the group consisting of nucleic acid sequences: (a) having at least 10 70% identity with the nucleic acid sequence of SEQ ID NO:1 or SEQ ID NO: 48, (b) encoding a polypeptide having an amino acid sequence which has at least 50% identity with the amino acid sequence of SEQ ID NO:2 or SEQ ID NO: 49, (c) which hybridizes under low stringency conditions with the nucleic acid sequence 15 of SEQ ID NO:1 or SEQ ID NO: 48, or its complementary strand, and (d) encoding a polypeptide having the amino acid sequence of SEQ ID NO:3.

The present invention also encompasses nucleic acid sequences which differ from SEQ ID NO:1 or SEQ ID NO: 48 by 20 virtue of the degeneracy of the genetic code. The present invention also relates to subsequences of SEQ ID NO:1 or SEQ ID NO: 49, wherein a subsequence of SEQ ID NO:1 is a nucleic acid sequence encompassed by SEQ ID NO:1 or SEQ ID NO: 48 except that one or more nucleotides from the 5' and/or 3' end have 25 been deleted. Preferably, a subsequence of SEQ ID NO:1 or SEQ ID NO: 48 encodes a polypeptide fragment which has transcriptional activation activity. In a more preferred embodiment, a subsequence of SEQ ID NO:1 or SEQ ID NO: 48 contains at least a nucleic acid sequence encoding the 30 polypeptide sequence shown in SEQ ID NO:3.

The techniques used to isolate or clone a nucleic acid sequence encoding a polypeptide are known in the art and include isolation from genomic DNA, preparation from cDNA, or a combination thereof. The cloning of the nucleic acid sequences

of the present invention from such genomic DNA can be effected, e.g., by using methods based on polymerase chain reaction (PCR) or antibody screening of expression libraries to detect cloned DNA fragments with shared structural features. (See, e.g., 5 Innis et al., 1990, *PCR: A Guide to Methods and Application*, Academic Press, New York.) Other nucleic acid amplification procedures such as ligase chain reaction (LCR), ligated activated transcription (LAT) and nucleic acid sequence-based amplification (NASBA) may be used. The nucleic acid sequence 10 may be cloned from a microorganism, or another or related organism and thus, for example, may be an allelic or species variant of the polypeptide encoding region of the nucleic acid sequence.

The transcriptional activators encoded by nucleic acid 15 sequences which hybridize with an oligonucleotide probe which hybridizes with the nucleic acid sequence of SEQ ID NO:1 or SEQ ID NO: 48, its complementary strand, or allelic variants and subsequences of SEQ ID NO:1 or SEQ ID NO: 48, or allelic variants and fragments of the transcriptional activators may be 20 obtained from microorganisms of any genus.

In a preferred embodiment, the transcriptional activators may be obtained from a fungal cell. "Fungi" as used herein includes the phyla Ascomycota, Basidiomycota, Chytridiomycota, and Zygomycota (as defined by Hawksworth, et al., in Ainsworth 25 and Bisby's *Dictionary of The Fungi*, 8th edition, 1995, CAB International, University Press, Cambridge, UK) as well as the Oomycota (as cited in Hawksworth et al., 1995, *supra*, page 171) and all mitosporic fungi (Hawksworth et al., 1995, *supra*).

In preferred embodiment, the fungal source is a filamentous 30 fungal strain. "Filamentous fungi" include all filamentous forms of the subdivision Eumycota and Oomycota (as defined by Hawksworth et al., 1995, *supra*). The filamentous fungi are characterized by a mycelia wall composed of chitin, cellulose, glucan, chitosan, mannan, and other complex polysaccharides.

Vegetative growth is by hyphal elongation and carbon catabolism is obligately aerobic. Filamentous fungal strains include, but are not limited to, strains of *Acremonium*, *Aspergillus*, *Aureobasidium*, *Cryptococcus*, *Filibasidium*, *Fusarium*, *Humicola*, 5 *Magnaporthe*, *Mucor*, *Myceliophthora*, *Neocallimastix*, *Neurospora*, *Paecilomyces*, *Penicillium*, *Piromyces*, *Schizophyllum*, *Talaromyces*, *Thermoascus*, *Thielavia*, *Tolypocladium*, and *Trichoderma*.

In a more preferred embodiment, the nucleic acid sequence 10 encoding a transcriptional activator of the present invention is obtained from a strain of *Aspergillus*, such as *A. awamori* or *A. nidulans*. Preferably, the nucleic acid sequence is obtained from a strain of *A. niger* or *A. oryzae*. Even more preferably, the nucleic acid sequence is obtained from an isolate of a 15 strain of *A. niger*, DSM 12298; e.g., the nucleic acid sequence set forth in SEQ ID NO:1 , or from *A. oryzae* IFO 4177, i.e., the nucleic acid sequence set forth in SEQ ID NO: 48.

In another more preferred embodiment, the nucleic acid sequence encoding a transcriptional activator of the present 20 invention is obtained from a strain of *Fusarium*, such as *F. oxysporum*. Preferably, the strain is a strain of *F. venenatum* (Nirenberg sp. nov.).

In another preferred embodiment, the nucleic acid sequence encoding a transcriptional activator of the present invention 25 is obtained from a yeast strain, such as a *Candida*, *Kluyveromyces*, *Schizosaccharomyces*, or *Yarrowia* strain. Preferably, the strain is a strain of *Hansenula*, *Pichia*, or *Saccharomyces*.

It will be understood that for the aforementioned species, 30 the invention encompasses both the perfect and imperfect states, and other taxonomic equivalents, e.g., anamorphs, regardless of the species name by which they are known. Those skilled in the art will readily recognize the identity of appropriate equivalents. For example, the polypeptides may be

obtained from microorganisms, which are taxonomic equivalents of *Aspergillus* as defined by Raper, K.D. and Fennel, D.I. (1965. *The Genus Aspergillus*, The Wilkins Company, Baltimore MD). regardless of the species name by which they are known.

5 *Aspergilli* are mitosporic fungi characterized by an aspergillum comprised of a conidiospore stipe with no known teleomorphic states terminating in a vesicle, which in turn bears one or two layers of synchronously formed specialized cells, variously referred to as sterigmata or phialides, and asexually formed

10 spores referred to as conidia. Known teleomorphs of *Aspergillus* include *Eurotium*, *Neosartorya*, and *Emericella*. Strains of *Aspergillus* and teleomorphs thereof are readily accessible to the public in a number of culture collections, such as the American Type Culture Collection (ATCC), Deutsche

15 Sammlung von Mikroorganismen und Zellkulturen GmbH (DSM), Centraalbureau Voor Schimmelcultures (CBS), and Agricultural Research Service Patent Culture Collection, Northern Regional Research Center (NRRL).

Furthermore, such transcriptional activators may be

20 identified and obtained from other sources including microorganisms isolated from nature (e.g., soil, composts, water, etc.) using the above-mentioned probes. Techniques for isolating microorganisms from natural habitats are well known in the art. The nucleic acid sequence may then be derived by

25 similarly screening a genomic or cDNA library of another microorganism. Once a nucleic acid sequence encoding a transcriptional activator has been detected with the probe(s), the sequence may be isolated or cloned by utilizing techniques which are known to those of ordinary skill in the art (see,

30 e.g., J. Sambrook, E.F. Fritsch, and T. Maniatis, 1989, *Molecular Cloning, A Laboratory Manual*, 2d edition, Cold Spring Harbor, New York).

In another preferred embodiment, the isolated nucleic acid sequence encodes a polypeptide comprising the amino acid

sequence of SEQ ID NO: 2 or SEQ ID NO: 49, or a fragment thereof, which has transcriptional activation activity.

In another preferred embodiment, the isolated nucleic acid sequence encodes a polypeptide comprising the amino acid sequence of SEQ ID NO: 3.

The present invention also relates to isolated nucleic acid sequences encoding a transcriptional activator of the present invention, which, e.g., using methods of standard Southern blotting procedures described above (cf., Sambrook, et al., 1989, *supra*), hybridize under low stringency conditions, more preferably medium stringency conditions, and most preferably high stringency conditions, with an oligonucleotide probe which hybridizes under the same conditions with the nucleic acid sequence set forth in SEQ ID NO:1 or SEQ ID NO: 48 or its complementary strand, or allelic variants and subsequences of SEQ ID NO:1 or SEQ ID NO: 48 which encode polypeptide fragments which are transcriptional activators in fungi.

In another more preferred embodiment, the nucleic acid sequence is the nucleic acid sequence encoding a polypeptide, which has DNA binding activity contained in the plasmid pEES which is contained in *Escherichia coli* DSM 12294.

Nucleic Acid Constructs

Another aspect of the present invention relates to nucleic acid constructs comprising a nucleic acid sequence encoding a transcriptional activator of the present invention operably linked to one or more control sequences, which direct the production of the transcriptional activator in a suitable expression host. In a preferred embodiment, the nucleic acid sequence encodes a polypeptide, which is contained in the plasmid pEES harboured in *Escherichia coli* DSM 12294, or the nucleic acid sequence shown in SEQ ID NO: 48 encoding the polypeptide shown in SEQ ID NO: 49.

Expression will be understood to include any step involved in the production of the polypeptide including, but not limited to, transcription, post-transcriptional modification, translation, post-translational modification, and secretion.

- 5 Manipulation of the nucleic acid sequence encoding a polypeptide prior to its insertion into a vector may be desirable or necessary depending on the expression vector. The techniques for modifying nucleic acid sequences utilizing cloning methods are well known in the art.
- 10 "Nucleic acid construct" is defined herein as a nucleic acid molecule, either single- or double-stranded, which is isolated from a naturally occurring gene or which has been modified to contain segments of nucleic acid which are combined and juxtaposed in a manner which would not otherwise exist in nature. The term nucleic acid construct is synonymous with the term expression cassette when the nucleic acid construct contains all the control sequences required for expression of a coding sequence. The term "coding sequence" as defined herein is a sequence, which is transcribed into mRNA and translated
- 15 into a transcriptional activator of the present invention. The boundaries of the coding sequence are generally determined by the ATG start codon at the 5' end of the mRNA and a transcription terminator sequence located just downstream of the open reading frame at the 3' end of the mRNA. A coding sequence can include, but is not limited to, DNA, cDNA, and recombinant nucleic acid sequences.
- 20
- 25

The term "control sequences" is defined herein to include all components, which are necessary or advantageous for the expression of a polypeptide. Each control sequence may be native or foreign to the nucleic acid sequence encoding the polypeptide. Such control sequences include, but are not limited to, a leader, a polyadenylation sequence, a propeptide sequence, a promoter, a signal sequence, and a transcription terminator. At a minimum, the control sequences include a

30

promoter, and transcriptional and translational stop signals. The control sequences may be provided with linkers for the purpose of introducing specific restriction sites facilitating ligation of the control sequences with the coding region of the 5 nucleic acid sequence encoding a polypeptide. The term "operably linked" is defined herein as a configuration in which a control sequence is appropriately placed at a position relative to the coding sequence of the DNA sequence such that the control sequence directs the production of a polypeptide.

10 The control sequence may be an appropriate promoter sequence, a nucleic acid sequence, which is recognized by a host cell for expression of the nucleic acid sequence. The promoter sequence contains transcriptional control sequences, which mediate the expression of the polypeptide. The promoter 15 may be any nucleic acid sequence, which shows transcriptional activity in the cell including mutant, truncated, and hybrid promoters, and may be obtained from genes encoding extracellular or intracellular polypeptides either homologous or heterologous to the cell.

20 The control sequence may also be a suitable transcription terminator sequence, a sequence recognized by a filamentous fungal cell to terminate transcription. The terminator sequence is operably linked to the 3' terminus of the nucleic acid sequence encoding the polypeptide. Any terminator, which 25 is functional in the cell, may be used in the present invention.

Preferred terminators for filamentous fungal cells are obtained from the genes encoding *Aspergillus oryzae* TAKA amylase, *Aspergillus niger* glucoamylase, *Aspergillus nidulans* 30 anthranilate synthase, *Aspergillus niger* alpha-glucosidase, and *Fusarium oxysporum* trypsin-like protease.

The control sequence may also be a suitable leader sequence, a nontranslated region of a mRNA which is important for translation by the filamentous fungal cell. The leader

sequence is operably linked to the 5' terminus of the nucleic acid sequence encoding the polypeptide. Any leader sequence, which is functional in the cell, may be used in the present invention.

5 Preferred leaders for filamentous fungal cells are obtained from the genes encoding *Aspergillus oryzae* TAKA amylase and *Aspergillus nidulans* triose phosphate isomerase.

The control sequence may also be a polyadenylation sequence, a sequence which is operably linked to the 3' terminus of the 10 nucleic acid sequence and which, when transcribed, is recognized by the filamentous fungal cell as a signal to add polyadenosine residues to transcribed mRNA. Any polyadenylation sequence, which is functional in the cell, may be used in the present invention.

15 Preferred polyadenylation sequences for filamentous fungal cells are obtained from the genes encoding *Aspergillus oryzae* TAKA amylase, *Aspergillus niger* glucoamylase, *Aspergillus nidulans* anthranilate synthase, and *Aspergillus niger* alpha-glucosidase.

20 The control sequence may also be a signal peptide-coding region, which codes for an amino acid sequence linked to the amino terminus of the polypeptide, which can direct the encoded polypeptide into the cell's secretory pathway. The 5' end of the coding sequence of the nucleic acid sequence may inherently 25 contain a signal peptide-coding region naturally linked in translation reading frame with the segment of the coding region, which encodes the secreted polypeptide. Alternatively, the 5' end of the coding sequence may contain a signal peptide-coding region, which is foreign to the coding sequence. The 30 foreign signal peptide-coding region may be required where the coding sequence does not normally contain a signal peptide-coding region. Alternatively, the foreign signal peptide-coding region may simply replace the natural signal peptide-coding region in order to obtain enhanced secretion of the

polypeptide. The signal peptide-coding region may be obtained from a glucoamylase or an amylase gene from an *Aspergillus* species, or a lipase or proteinase gene from a *Rhizomucor* species. However, any signal peptide-coding region, which 5 directs the expressed polypeptide into the secretory pathway of a filamentous fungal cell, may be used in the present invention.

An effective signal peptide coding region for filamentous fungal cells is the signal peptide coding region obtained from 10 the *Aspergillus oryzae* TAKA amylase gene, *Aspergillus niger* neutral amylase gene, *Rhizomucor miehei* aspartic proteinase gene, or *Humicola lanuginosa* cellulase gene.

The control sequence may also be a propeptide coding region, which codes for an amino acid sequence positioned at the amino 15 terminus of a polypeptide. The resultant polypeptide is known as a proenzyme or propolypeptide (or a zymogen in some cases). A propolypeptide is generally inactive and can be converted to a mature active polypeptide by catalytic or autocatalytic cleavage of the propeptide from the propolypeptide. The 20 propeptide coding region may be obtained from the *Rhizomucor miehei* aspartic proteinase gene, or the *Myceliophthora thermophila* laccase gene (WO 95/33836).

Where both signal peptide and propeptide regions are present at the amino terminus of a polypeptide, the propeptide region 25 is positioned next to the amino terminus of a polypeptide and the signal peptide region is positioned next to the amino terminus of the propeptide region.

Expression Vectors

30 The present invention also relates to recombinant expression vectors comprising a nucleic acid sequence of the present invention, a promoter, and transcriptional and translational stop signals. The various nucleic acid and control sequences described above may be joined together to produce a recombinant

expression vector which may include one or more convenient restriction sites to allow for insertion or substitution of the nucleic acid sequence encoding the polypeptide at such sites. Alternatively, the nucleic acid sequence encoding the 5 polypeptide may be expressed by inserting the sequence or a nucleic acid construct comprising the sequence into an appropriate vector for expression. In creating the expression vector, the coding sequence is located in the vector so that the coding sequence is operably linked with the appropriate 10 control sequences for expression, and possibly secretion.

The recombinant expression vector may be any vector (e.g., a plasmid or virus), which can be conveniently subjected to recombinant DNA procedures and can bring about the expression of the nucleic acid sequence encoding the polypeptide. The 15 choice of the vector will typically depend on the compatibility of the vector with the filamentous fungal cell into which the vector is to be introduced. The vectors may be linear or closed circular plasmids. The vector may be an autonomously replicating vector, i.e., a vector, which exists as an 20 extrachromosomal entity, the replication of which is independent of chromosomal replication, e.g., a plasmid, an extrachromosomal element, a minichromosome, or an artificial chromosome. The vector may contain any means for assuring self-replication. Alternatively, the vector may be one which, 25 when introduced into the filamentous fungal cell, is integrated into the genome and replicated together with the chromosome(s) into which it has been integrated. The vector system may be a single vector or plasmid or two or more vectors or plasmids, which together contain the total DNA to be introduced into the 30 genome of the filamentous fungal cell, or a transposon.

The vectors preferably contain one or more selectable markers, which permit easy selection of transformed cells. A selectable marker is a gene the product of which provides for biocide or viral resistance, resistance to heavy metals,

prototrophy to auxotrophs, and the like. A selectable marker for use in a filamentous fungal cell may be selected from the group including, but not limited to, *amds* (acetamidase), *argB* (ornithine carbamoyltransferase), *bar* (phosphinothricin acetyltransferase), *hygB* (hygromycin phosphotransferase), *niaD* (nitrate reductase), *pyrG* (orotidine-5'-phosphate decarboxylase), *sC* (sulfate' adenyltransferase), and *trpC* (anthranilate synthase), as well as equivalents from other species. Preferred for use in an *Aspergillus* cell are the *amds* and *pyrG* genes of *Aspergillus nidulans* or *Aspergillus oryzae* and the *bar* gene of *Streptomyces hygroscopicus*.

The vectors preferably contain an element(s) that permits stable integration of the vector into the host cell genome or autonomous replication of the vector in the cell independent of the genome of the cell.

Host Cells

Another aspect of the present invention relates to host cells comprising a nucleic acid construct or an expression vector of the present invention.

The choice of a host cell in the methods of the present invention will to a large extent depend upon the source of the nucleic acid sequence encoding the polypeptide of interest.

The introduction of an expression vector or a nucleic acid construct into a filamentous fungal cell may involve a process consisting of protoplast formation, transformation of the protoplasts, and regeneration of the cell wall in a manner known *per se*. Suitable procedures for transformation of *Aspergillus* cells are described in EP 238 023 and Yelton et al., 1984, *Proceedings of the National Academy of Sciences USA* 81: 1470-1474. A suitable method of transforming *Fusarium* species is described by Malardier et al., 1989, *Gene* 78: 147-156 or in WO 96/00787.

"Introduction" means introducing a vector comprising the nucleic acid sequence encoding the polypeptide into a filamentous fungal cell so that the vector is maintained as a chromosomal integrant or as a self-replicating extra-
5 chromosomal vector. Integration is generally considered to be an advantage as the nucleic acid sequence is more likely to be stably maintained in the cell. Integration of the vector into the chromosome occurs by homologous recombination, non-homologous recombination, or transposition.

10 For integration into the host cell genome, the vector may rely on the nucleic acid sequence encoding the polypeptide or any other element of the vector for stable integration of the vector into the genome by homologous or nonhomologous recombination. Alternatively, the vector may contain
15 additional nucleic acid sequences for directing integration by homologous recombination into the genome of the host cell. The additional nucleic acid sequences enable the vector to be integrated into the host cell genome at a precise location(s) in the chromosome(s). To increase the likelihood of
20 integration at a precise location, the integrational elements should preferably contain a sufficient number of nucleic acids, such as 100 to 1,500 base pairs, preferably 400 to 1,500 base pairs, and most preferably 800 to 1,500 base pairs, which are highly homologous with the corresponding target sequence to
25 enhance the probability of homologous recombination. The integrational elements may be any sequence that is homologous with the target sequence in the genome of the host cell. These nucleic acid sequences may be any sequence that is homologous with a target sequence in the genome of the host cell, and,
30 furthermore, may be non-encoding or encoding sequences.

For autonomous replication, the vector may further comprise an origin of replication enabling the vector to replicate autonomously in the host cell.

The procedures used to ligate the elements described above to construct the recombinant expression vectors are well known to one skilled in the art (see, e.g., Sambrook, et al., *supra*).

In a preferred embodiment, the filamentous fungal host cell 5 is a cell of a species of, but not limited to, *Acremonium*, *Aspergillus*, *Fusarium*, *Humicola*, *Mucor*, *Myceliophthora*, *Neurospora*, *Penicillium*, *Thielavia*, *Tolypocladium*, or *Trichoderma*.

In a more preferred embodiment, the filamentous fungal cell 10 is an *Aspergillus* cell. In another more preferred embodiment, the filamentous fungal cell is an *Acremonium* cell. In another more preferred embodiment, the filamentous fungal cell is a *Fusarium* cell. In another more preferred embodiment, the filamentous fungal cell is a *Humicola* cell. In another more 15 preferred embodiment, the filamentous fungal cell is a *Mucor* cell. In another more preferred embodiment, the filamentous fungal cell is a *Myceliophthora* cell. In another more preferred embodiment, the filamentous fungal cell is a *Neurospora* cell. In another more preferred embodiment, the 20 filamentous fungal cell is a *Penicillium* cell. In another more preferred embodiment, the filamentous fungal cell is a *Thielavia* cell. In another more preferred embodiment, the filamentous fungal cell is a *Tolypocladium* cell. In another more preferred embodiment, the filamentous fungal cell is a 25 *Trichoderma* cell.

In a most preferred embodiment, the filamentous fungal cell is an *Aspergillus awamori*, *Aspergillus foetidus*, *Aspergillus japonicus*, *Aspergillus nidulans*, *Aspergillus niger* or *Aspergillus oryzae* cell. In another most preferred embodiment, 30 the filamentous fungal cell is a *Fusarium bactridioides*, *Fusarium cerealis*, *Fusarium crookwellense*, *Fusarium culmorum*, *Fusarium graminearum*, *Fusarium gramininum*, *Fusarium heterosporum*, *Fusarium negundi*, *Fusarium oxysporum*, *Fusarium reticulatum*, *Fusarium roseum*, *Fusarium sambucinum*, *Fusarium sarcochroum*,

Fusarium sulphureum, *Fusarium toruloseum*, *Fusarium trichothecioides*, or *Fusarium venenatum* cell. In an even most preferred embodiment, the filamentous fungal cell is a *Fusarium venenatum* (Nirenberg sp. nov.). In another most preferred 5 embodiment, the filamentous fungal cell is a *Humicola insolens* or *Humicola lanuginosa* cell. In another most preferred embodiment, the filamentous fungal cell is a *Mucor miehei* cell. In another most preferred embodiment, the filamentous fungal cell is a *Myceliophthora thermophilum* cell. In another most 10 preferred embodiment, the filamentous fungal cell is a *Neurospora crassa* cell. In another most preferred embodiment, the filamentous fungal cell is a *Penicillium purpurogenum* cell. In another most preferred embodiment, the filamentous fungal cell is a *Thielavia terrestris* cell. In another most preferred 15 embodiment, the *Trichoderma* cell is a *Trichoderma harzianum*, *Trichoderma koningii*, *Trichoderma longibrachiatum*, *Trichoderma reesei* or *Trichoderma viride* cell.

Polypeptides having Transcriptional Activation Activity

20 Another aspect of the present invention relates to an isolated polypeptide selected from the group consisting of:

(a) a polypeptide which is encoded in a nucleic acid sequence which hybridizes under low stringency conditions with (i) the nucleic acid sequence of SEQ ID NO:1 or SEQ 25 ID NO: 48; (ii) its complementary strand, or (iii) a subsequence of SEQ ID NO:1 or SEQ ID NO: 48 which encodes a polypeptide fragment which has transcriptional activation activity, wherein the low stringency conditions are defined by prehybridization and 30 hybridization at 42°C in 5X SSPE, 0.3% SDS, 200 micro g/ml sheared and denatured salmon sperm DNA, and 25% formamide, and wash conditions are defined at 50°C for 30 minutes in 2X SSC, 0.2% SDS;

- (b) a polypeptide having an amino acid sequence which has at least 50% identity with the amino acid sequence of SEQ ID NO:2 or SEQ ID NO: 49;
- (c) an allelic variant of (a) or (b);
- 5 (d) a fragment of (a), (b), or (c), wherein the fragment has transcriptional activation activity; and
- (e) a polypeptide comprising the amino acid sequence of SEQ ID NO:3, or an allelic variant thereof.

The transcriptional activator may be isolated using 10 techniques as described herein. As defined herein, an "isolated" polypeptide is a polypeptide which is essentially free of other polypeptides, e.g., at least about 20% pure, preferably at least about 40% pure, more preferably about 60% pure, even more preferably about 80% pure, most preferably 15 about 90% pure, and even most preferably about 95% pure, as determined by SDS-PAGE.

The present invention also relates to isolated polypeptides having an amino acid sequence which has a degree of identity to the amino acid sequence of SEQ ID NO:2 or SEQ ID NO: 49 of at 20 least about 50%, preferably at least about 55%, preferably at least about 60%, preferably at least about 65%, preferably at least about 70%, preferably at least about 75%, preferably at least about 80%, more preferably at least about 85%, even more preferably at least about 90%, most preferably at least about 25 95%, and even most preferably at least about 97%, even more preferred at least 99%, which have transcriptional activation activity.

In more preferred embodiment, the transcriptional activator of the present invention comprises the amino acid sequence of 30 SEQ ID NO:2 or SEQ ID NO: 49 or a fragment thereof, wherein the fragment retains transcriptional activation activity. In a most preferred embodiment, the polypeptide has the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 49. A fragment of SEQ ID NO: 2 or SEQID NO: 49 is a polypeptide having one or more

amino acids deleted from the amino and/or carboxy terminus of this amino acid sequence. Preferably, a fragment of SEQ ID NO:2 or SEQ ID NO: 49 contains at least the polypeptide sequence shown in SEQ ID NO:3.

- 5 The amino acid sequences of the homologous polypeptides may differ from the amino acid sequence of SEQ ID NO:2 or SEQ ID NO: 49 or SEQ ID NO:3 by an insertion or deletion of one or more amino acid residues and/or the substitution of one or more amino acid residues by different amino acid residues.
- 10 Preferably, amino acid changes are of a minor nature, that is conservative amino acid substitutions that do not significantly affect the folding and/or activity of the protein; small deletions, typically of one to about 30 amino acids; small amino- or carboxyl-terminal extensions, such as an amino-
- 15 terminal methionine residue; a small linker peptide of up to about 20-25 residues; or a small extension that facilitates purification by changing net charge or another function, such as a poly-histidine tract, an antigenic epitope or a binding domain.
- 20 Examples of conservative substitutions are within the group of basic amino acids (such as arginine, lysine and histidine), acidic amino acids (such as glutamic acid and aspartic acid), polar amino acids (such as glutamine and asparagine), hydrophobic amino acids (such as leucine, isoleucine and
- 25 valine), aromatic amino acids (such as phenylalanine, tryptophan and tyrosine), and small amino acids (such as glycine, alanine, serine, threonine and methionine). Amino acid substitutions, which do not generally alter the specific activity are known in the art and are described, for example,
- 30 by H. Neurath and R.L. Hill (1979. *The Proteins*, Academic Press, New York). The most commonly occurring exchanges are Ala/Ser, Val/Ile, Asp/Glu, Thr/Ser, Ala/Gly, Ala/Thr, Ser/Asn, Ala/Val, Ser/Gly, Tyr/Phe, Ala/Pro, Lys/Arg, Asp/Asn, Leu/Ile, Leu/Val, Ala/Glu, and Asp/Gly as well as these in reverse.

In a more preferred embodiment, a transcriptional activator of the present invention is obtained from an *Aspergillus niger* strain, more preferably from *Aspergillus niger* AB4.1 (van Haringsveldt, W., et al., 1987. Mol. Gen. Genet. 206:71-75), and most preferably from *Aspergillus niger* 13PAP2, which has been deposited at DSM as DSM 12298, or a mutant strain thereof, harbouring, e.g., the polypeptide with the amino acid sequence of SEQ ID NO:2 or SEQ ID NO: 49 or SEQ ID NO:3.

In another preferred embodiment, the transcriptional activator of the present invention is the polypeptide encoded in the nucleic acid sequence contained in plasmid pEES, which is contained in *Escherichia coli* DSM 12294 or the nucleic acid sequence shown in SEQ ID NO: 48 encoding the polypeptide shown in SEQ ID NO: 49.

The present invention further relates to methods for producing the transcriptional activator of the present invention comprising (a) cultivating a host cell harbouring a nucleic acid construct or an expression vector comprising a nucleic acid sequence encoding the transcriptional activator of the invention under conditions conducive for production of the polypeptide; and (b) recovering the polypeptide.

Host Cells having Altered Transcriptional Activation Activity

Another aspect of the present invention relates to a host cell which is a mutant of a parent fungal cell useful for the production of a polypeptide in which the parent cell comprises one or more nucleic acid sequences encoding a protease, the transcription of which is activated by a transcriptional activator of the present invention, and the mutant cell produces less of the transcriptional activator and the protease(s) than the parent cell when cultured under the same conditions.

The mutant cell may be constructed using methods well known in the art; for example, by one or more nucleotide insertions or deletions of the gene encoding the transcriptional activator.

In a preferred embodiment the mutant cell is obtained by 5 modification or inactivation of a nucleic acid sequence present in the cell and necessary for expression of the transcriptional activator.

In a more preferred embodiment, the nucleic acid sequence is selected from the group consisting of: (a) a nucleic acid 10 sequence having at least 70% identity with the nucleic acid sequence of SEQ ID NO:1 or SEQ ID NO: 48; (b) a nucleic acid sequence encoding a polypeptide having an amino acid sequence which has at least 50% identity with the amino acid sequence of SEQ ID NO:2 or SEQ ID NO: 49; (c) a nucleic acid sequence which 15 hybridizes under low stringency conditions with (i) the nucleic acid sequence of SEQ ID NO:1 or SEQ ID NO: 48, or (ii) its complementary strand, (d) an allelic variant of (a), (b), or (c); (e) a subsequence of (a), (b), (c), or (d), wherein the subsequence encodes a polypeptide fragment which has 20 transcriptional activation activity; and (f) a subsequence of (a), (b) (c), or (d), wherein the subsequence encodes a polypeptide with the amino acid sequence of SEQ ID NO:3.

In another preferred embodiment the reduced expression of the transcriptional activator in the mutant cell is obtained by 25 modification or inactivation of a control sequence required for the expression of the transcriptional activator. The term "control sequence" is defined, *supra*, in the section entitled "Nucleic Acid Constructs." In a more preferred embodiment the control sequence in the mutant cell is a promoter sequence or a 30 functional part thereof, *i.e.*, a part, which is sufficient for affecting expression of the nucleic acid sequence. Other control sequences for possible modification include, but are not limited to, a leader, a polyadenylation sequence, a

propeptide sequence, a signal sequence, and a transcription terminator.

Modification or inactivation of the gene may be performed by subjecting the parent cell to mutagenesis and selecting for 5 mutant cells in which the capability to produce a transcriptional activator has been reduced. The mutagenesis, which may be specific or random, may be performed, for example, by use of a suitable physical or chemical mutagenizing agent, by use of a suitable oligonucleotide, or by subjecting the DNA 10 sequence to PCR generated mutagenesis. Furthermore, the mutagenesis may be performed by use of any combination of these mutagenizing agents.

Examples of a physical or chemical mutagenizing agent suitable for the present purpose include ultraviolet (UV) 15 irradiation, hydroxylamine, N-methyl-N'-nitro-N-nitrosoguanidine (MNNG), O-methyl hydroxylamine, nitrous acid, ethyl methane sulphonate (EMS), sodium bisulphite, formic acid, and nucleotide analogues.

When such agents are used, the mutagenesis is typically 20 performed by incubating the parent cell to be mutagenized in the presence of the mutagenizing agent of choice under suitable conditions, and selecting for mutant cells exhibiting reduced expression of the gene.

Modification or inactivation of the gene may be accomplished 25 by introduction, substitution, or removal of one or more nucleotides in the gene's nucleic acid sequence or a regulatory element required for the transcription or translation thereof. For example, nucleotides may be inserted or removed so as to result in the introduction of a stop codon, the removal of the 30 start codon, or a change of the open reading frame. Such modification or inactivation may be accomplished by site-directed mutagenesis or PCR generated mutagenesis in accordance with methods known in the art. Although, in principle, the modification may be performed *in vivo*, i.e., directly on the

fungal cell expressing the gene to be modified, it is preferred that the modification be performed *in vitro* as exemplified below.

An example of a convenient way to inactivate or reduce expression of the gene by a fungal cell of choice is based on techniques of gene replacement or gene interruption. For example, in the gene interruption method, a nucleic acid sequence corresponding to the endogenous gene or gene fragment of interest is mutagenized *in vitro* to produce a defective nucleic acid sequence which is then transformed into the parent cell to produce a defective gene. By homologous recombination, the defective nucleic acid sequence replaces the endogenous gene or gene fragment. It may be desirable that the defective gene or gene fragment also encodes a marker, which may be used for selection of transformants in which the nucleic acid sequence has been modified or destroyed.

Alternatively, modification or inactivation of the gene may be performed by established anti-sense techniques using a nucleotide sequence complementary to the nucleic acid sequence of the gene. More specifically, expression of the gene by a filamentous fungal cell may be reduced or eliminated by introducing a nucleotide sequence complementary to the nucleic acid sequence, which may be transcribed in the cell and is capable of hybridizing to the mRNA produced in the cell. Under conditions allowing the complementary anti-sense nucleotide sequence to hybridize to the mRNA, the amount of protein translated is thus reduced or eliminated.

A nucleic acid sequence complementary to the nucleic acid sequence of SEQ ID NO:1 or SEQ ID NO: 48 may be obtained from any microbial source. The preferred sources are fungal sources, e.g., yeast and filamentous fungi as described *supra*. Preferred filamentous fungal sources include, but are not limited to, species of *Acremonium*, *Aspergillus*, *Fusarium*, *Humicola*, *Myceliophthora*, *Mucor*, *Neurospora*, *Penicillium*,

Phanerochaete, *Thielavia*, *Tolypocladium*, and *Trichoderma*. Preferred yeast sources include, but are not limited to, species of *Candida*, *Hansenula*, *Kluyveromyces*, *Pichia*, *Saccharomyces*, *Schizosaccharomyces*, and *Yarrowia*. Furthermore, 5 the nucleic acid sequence may be native to the filamentous fungal cell.

In another preferred embodiment, the parent cell harbours a gene having a nucleic acid sequence encoding a polypeptide with an amino acid sequence which has at least 50% identity with the 10 amino acid sequence of SEQ ID NO:2 or SEQID NO: 49.

In another preferred embodiment, the parent cell harbours a gene having a nucleic acid sequence with at least 70% identity with the nucleic acid sequence of SEQ ID NO:1 or SEQ ID NO: 48.

In another preferred embodiment, the mutant cell harbours a 15 nucleic acid sequence, which has been modified or inactivated by any of the methods described above and produces less of a protease or a combination of proteases than the parent cell when cultured under identical conditions. The mutant cell produces preferably at least about 25% less, more preferably at least 20 about 50% less, even more preferably at least about 75% less, and even more preferably at least about 95% less of a protease or a combination of proteases than the parent cell when cultured under identical conditions.

In an even more preferred embodiment, the mutant cell 25 produces essentially undetectable amounts of a protease or combination of proteases than the parent cell when cultured under identical conditions.

The protease(s) may be assayed using known methods. In one such method, an aliquot of a 48 hour culture media is incubated 30 with ³H-labelled sperm whale myoglobin at pH 4.0 and the radioactivity in the TCA-soluble fraction is measured (van Noort, J.M., et al., 1991. Anal. Biochem 198:385-390). Other methods have been described for identifying, e.g., aspartic proteinase A. of *A. niger* (Takahashi, K., 1991. Meth. in

Enzymol. 248:146-155), endopeptidases (Morihara, K., 1995. Meth. in Enzymol. 248:242-253), carboxypeptidases (Reminton, J., and Breddam, K., 1994. Meth. in Enzymol. 244:231-248), dipeptidyl peptidase (Ikehara, Y., et al., 244:215-227), and 5 aminopeptidases (Little, G., et al., 1976. Meth. in Enzymol. 45:495-503).

In another preferred embodiment, the mutant cell harbours at least one copy of a nucleic acid sequence encoding a polypeptide of interest.

10 Another aspect of the present invention relates to a host cell useful for the production of a polypeptide wherein the host cell is a mutant of a parent fungal cell in which the mutant (a) produces more of the transcriptional activator of the present invention as compared to the parent cell when 15 cultured under the same conditions; and (b) comprises a DNA sequence encoding the polypeptide, the transcription of which is activated by the transcriptional activator.

In a preferred embodiment, the host cell produces more of the transcriptional activator than the parent cell when 20 cultured under the same conditions by introducing into the parent cell one or more copies of (i) a nucleic acid sequence encoding a transcriptional activator, (ii) a nucleic acid construct comprising a nucleic acid sequence encoding a transcriptional activator, or (iii) an expression vector as 25 defined above in the section "Expression Vectors".

The nucleic acid construct comprising a nucleic acid sequence encoding a transcriptional activator of the present invention may also comprise one or more nucleic acid sequences which encode one or more factors that are advantageous for 30 directing the expression of the polypeptide, e.g., a transcriptional activator (e.g., a *trans*-acting factor), a chaperone, and a processing protease. Any factor that is functional in the filamentous fungal cell of choice may be used in the present invention. The nucleic acids encoding one or

more of these factors are not necessarily in tandem with the nucleic acid sequence encoding the polypeptide.

An activator is a protein, which activates transcription of a nucleic acid sequence encoding a polypeptide (Kudla et al., 5 1990, *EMBO Journal* 9: 1355-1364; Jarai and Buxton, 1994, *Current Genetics* 26: 2238-244; Verdier, 1990, *Yeast* 6: 271-297). The nucleic acid sequence encoding an activator may be obtained from the genes encoding *Saccharomyces cerevisiae* heme activator protein 1 (*hap1*), *Saccharomyces cerevisiae* galactose 10 metabolizing protein 4 (*gal4*), *Aspergillus nidulans* ammonia regulation protein (*areA*), and *Aspergillus oryzae* alpha-amylase activator (*amyR*). For further examples, see Verdier, 1990, *supra* and MacKenzie et al., 1993, *Journal of General Microbiology* 139: 2295-2307.

15 A chaperone is a protein which assists another polypeptide in folding properly (Hartl et al., 1994, *TIBS* 19: 20-25; Bergeron et al., 1994, *TIBS* 19: 124-128; Demolder et al., 1994, *Journal of Biotechnology* 32: 179-189; Craig, 1993, *Science* 260: 1902-1903; Gething and Sambrook, 1992, *Nature* 355: 33-45; Puig 20 and Gilbert, 1994, *Journal of Biological Chemistry* 269: 7764-7771; Wang and Tsou, 1993, *The FASEB Journal* 7: 1515-11157; Robinson et al., 1994, *Bio/Technology* 1: 381-384; Jacobs et al., 1993, *Molecular Microbiology* 8: 957-966). The nucleic acid sequence encoding a chaperone may be obtained from the 25 genes encoding *Aspergillus oryzae* protein disulphide isomerase or *Saccharomyces cerevisiae* calnexin, *Saccharomyces cerevisiae* BiP/GRP78, and *Saccharomyces cerevisiae* Hsp70. For further examples, see Gething and Sambrook, 1992, *supra*, and Hartl et al., 1994, *supra*.

30 A processing protease is a protease that cleaves a propeptide to generate a mature biochemically active polypeptide (Enderlin and Ogrydziak, 1994, *Yeast* 10: 67-79; Fuller et al., 1989, *Proceedings of the National Academy of Sciences USA* 86: 1434-1438; Julius et al., 1984, *Cell* 37: 1075-

1089; Julius et al., 1983, *Cell* 32: 839-852; U.S. Patent No. 5,702,934). The nucleic acid sequence encoding a processing protease may be obtained from the genes encoding *Saccharomyces cerevisiae* dipeptidylaminopeptidase, *Saccharomyces cerevisiae* 5 *Kex2*, *Yarrowia lipolytica* dibasic processing endoprotease (*xpr6*), and *Fusarium oxysporum* metalloprotease (p45 gene).

In a more preferred embodiment, the nucleic acid sequence encoding the transcriptional activator is operably linked to a promoter, or a functional part thereof, which is stronger than 10 the corresponding promoter of the parent cell. In an even more preferred embodiment, the promoter, or a functional part thereof, mediates the expression of a gene encoding an extracellular protease, such as the *Aspergillus oryzae* alkaline protease, *A. oryzae* neutral metalloprotease, *A. niger* 15 *aspergillopepsin* protease, *Fusarium oxysporum* trypsin-like protease or *F. venenatum* trypsin.

The present invention also relates to a host cell useful for the production of a polypeptide wherein the host cell is a mutant of a parent fungal cell in which the mutant comprises 20
a) a modification or inactivation of a transcriptional activator of the present invention, or a regulatory sequence thereof, and
b) (i) an inducible promoter operably linked to a nucleic acid sequence encoding a transcriptional activator of the present invention, and (ii) a promoter sequence to which the transcriptional activator can bind, operably linked to a nucleic acid sequence encoding the polypeptide, wherein (i) and (ii) can be introduced simultaneously or sequentially.
25

30

The inactive form of the transcriptional activator in (a) above is obtained by inactivation or modification of a nucleic acid sequence present in the cell and necessary for the expression of the native transcriptional activator according to

any of the methods as disclosed *supra*. In a preferred embodiment the inactivation or modification is obtained by methods, which include, but are not limited to, one or more nucleotide insertions, deletions or substitutions, specific or 5 random mutagenesis, gene replacement or gene interruption, and anti-sense techniques using a nucleotide sequence complementary to the nucleic acid sequence of the transcriptional activator. In another preferred embodiment, the inactive form of the native transcriptional activator is obtained by inactivation or 10 modification of a control sequence required for the expression of the transcriptional activator.

In another preferred embodiment, the nucleic acid sequence encoding the native transcriptional activator has the sequence set forth in SEQ ID NO:1 or SEQ ID NO: 48. In another preferred 15 embodiment, the transcriptional activator comprises the polypeptide having the amino acid sequence in SEQ ID NO:3.

The inducible promoter sequence in (b) above may be any promoter sequence, or a functional part thereof, wherein the transcription initiation activity of the promoter can be 20 induced according to the fermentation conditions. Preferably, the induction is mediated by a carbon or nitrogen catabolite. In a preferred embodiment, the promoter is the *amdS* promoter of *Aspergillus nidulans* or *A. oryzae*, the *niaD* promoter of *A. nidulans*, *A. oryzae* or *A. niger*, the *niiA* promoter of 25 *Aspergillus* species, the alkaline phosphatase promoter of *Aspergillus* sp., the acid phosphatase promoter of *Aspergillus* sp., or the *alcA* promoter of *A. niger*.

In another preferred embodiment, the host cell further comprises a promoter sequence, wherein the promoter sequence 30 can be activated by the transcriptional activator and is operably linked to the nucleic acid sequence encoding the polypeptide.

The promoter sequence activated by the transcriptional activator of the present invention may be any promoter

sequence, or a functional part thereof, selected from the group which includes but is not limited to promoters obtained from the genes encoding *Aspergillus oryzae* TAKA amylase, *Rhizomucor miehei* aspartic proteinase, *Aspergillus niger* neutral alpha-amylase, *Aspergillus niger* acid stable alpha-amylase, *Aspergillus niger* or *Aspergillus awamori* glucoamylase (*glaA*), *Rhizomucor miehei* lipase, *Aspergillus oryzae* alkaline protease, *Aspergillus oryzae* triose phosphate isomerase, *Aspergillus nidulans* acetamidase, the NA2-tpi promoter (a hybrid of the promoters from the genes encoding *Aspergillus niger* neutral alpha-amylase and *Aspergillus oryzae* triose phosphate isomerase), and mutant, truncated, and hybrid promoters thereof. Particularly preferred promoters for use in filamentous fungal cells are a promoter, or a functional part thereof, from a protease gene; e.g., from the *Fusarium oxysporum* trypsin-like protease gene (U.S. Patent No. 4,288,627), *Aspergillus oryzae* alkaline protease gene (*alp*), *Aspergillus niger* *pacA* gene, *Aspergillus oryzae* alkaline protease gene, *A. oryzae* neutral metalloprotease gene, *A. niger* aspergillopepsin protease gene, or *F. venenatum* trypsin gene.

In another preferred embodiment, the host cell harbours at least one copy of a nucleic acid sequence encoding a polypeptide.

In another preferred embodiment, the host cell, which expresses the transcriptional activator of the present invention produces less of one or more native proteases than the parent cell when cultured under identical conditions. The protease(s) may be assayed using any of the methods described above. In a more preferred embodiment, an aliquot from a 48-hour culture media is incubated with ³H-labelled sperm whale myoglobin at pH 4.0 and the radioactivity in the TCA-soluble fraction is measured (van Noort, J.M., et al., *supra*).

The nucleic acid constructs described herein may be introduced into a parent fungal cell according to any of the

methods as described *supra* in the section, "Host Cells" to obtain a host cell useful for the production of a polypeptide. In a preferred embodiment the nucleic acid construct is integrated into the chromosome of the cell. In another 5 preferred embodiment the nucleic acid construct is maintained as a self-replicating extra-chromosomal vector.

It will be understood that the methods of the present invention are not limited to a particular order for obtaining the mutant fungal cell. The modification of the second nucleic 10 acid sequence may be introduced into the parent cell at any step in the construction of the cell for the production of a polypeptide.

Producing a Polypeptide

15 Another aspect of the present invention relates to methods of producing a polypeptide in a host cell of the present invention, comprising: (a) cultivating the host cell which harbours a gene encoding the polypeptide in a nutrient medium suitable for production of the polypeptide; and (b) recovering the 20 polypeptide from the nutrient medium of the host cell.

In one embodiment, the host cell which is a mutant of a parent fungal cell in which the parent cell comprises one or more nucleic acid sequences encoding a protease, the transcription of which is activated by a transcriptional 25 activator of the present invention, and the mutant cell produces less of the transcriptional activator and the protease(s) than the parent cell when cultured under the same conditions.

In another embodiment, the host cell is a mutant of a parent 30 fungal cell in which the mutant (a) produces more of the transcriptional activator of the present invention as compared to the parent cell when cultured under the same conditions; and (b) comprises a DNA sequence encoding the polypeptide, the

transcription of which is activated by the transcriptional activator.

In another embodiment, the host cell is a mutant of a parent fungal cell in which the mutant comprises (a) a modification or 5 inactivation of a transcriptional activator of the present invention or a regulatory sequence thereof, and (b) an inducible promoter operably linked to a nucleic acid sequence encoding a transcriptional activator of the present invention and a promoter sequence to which the transcriptional activator 10 can bind, operably linked to a nucleic acid sequence encoding the polypeptide, wherein (i) and (ii) can be introduced simultaneously or sequentially.

The host cells of the present invention are cultivated in a nutrient medium suitable for production of the polypeptide of 15 interest using methods known in the art. For example, the cells may be cultivated by shake flask cultivation, small-scale or large-scale fermentation (including continuous, batch, fed-batch, or solid state fermentations) in laboratory or industrial fermentors performed in a suitable medium and under 20 conditions allowing the polypeptide to be expressed and/or isolated. The cultivation takes place in a suitable nutrient medium comprising carbon and nitrogen sources and inorganic salts, using procedures known in the art (see, e.g., Bennett, J.W. and LaSure, L., eds., *More Gene Manipulations in Fungi*, 25 Academic Press, CA, 1991). Suitable media are available from commercial suppliers or may be prepared using published compositions (e.g., in catalogues of the American Type Culture Collection). If the polypeptide is secreted into the nutrient medium, the polypeptide can be recovered directly from the 30 medium. If the polypeptide is not secreted, it is recovered from cell lysates.

The resulting polypeptide may be isolated by methods known in the art. For example, the polypeptide may be isolated from the nutrient medium by conventional procedures including, but

not limited to, centrifugation, filtration, extraction, spray drying, evaporation, or precipitation. The isolated polypeptide may then be further purified by a variety of procedures known in the art including, but not limited to, 5 chromatography (e.g., ion exchange, affinity, hydrophobic, chromatofocusing, and size exclusion), electrophoretic procedures (e.g., preparative isoelectric focusing, differential solubility (e.g., ammonium sulfate precipitation), or extraction (see, e.g., *Protein Purification*, J.-C. Janson 10 and Lars Ryden, editors, VCH Publishers, New York, 1989).

The polypeptide may be detected using methods known in the art that are specific for the polypeptide. These detection methods may include use of specific antibodies, formation of an enzyme product, disappearance of an enzyme substrate, or SDS- 15 PAGE. For example, an enzyme assay may be used to determine the activity of the polypeptide. Procedures for determining enzyme activity are known in the art for many enzymes.

In the methods of the present invention, the host cell produces at least about 20% more, preferably at least about 50% 20 more, more preferably at least about 100% more, even more preferably at least about 200% more, and most preferably at least about 300% more of the polypeptide than a corresponding parent cell when cultivated under the same conditions.

The polypeptide may be any polypeptide whether native or 25 heterologous to the mutant filamentous fungal cell. The term "heterologous polypeptide" is defined herein as a polypeptide, which is not produced by a cell. The term "polypeptide" is not meant herein to refer to a specific length of the encoded produce and therefore encompasses peptides, oligopeptides and 30 proteins. The polypeptide may also be a recombinant polypeptide, which is a polypeptide native to a cell, which is encoded by a nucleic acid sequence, which comprises one or more control sequences, foreign to the nucleic acid sequence, which are involved in the production of the polypeptide. The

polypeptide may be a wild-type polypeptide or a variant thereof. The polypeptide may also be a hybrid polypeptide, which contains a combination of partial or complete polypeptide sequences obtained from at least two different polypeptides 5 where one or more of the polypeptides may be heterologous to the cell. Polypeptides further include naturally occurring allelic and engineered variations of the above-mentioned polypeptides.

In a preferred embodiment, the polypeptide is an antibody or 10 portions thereof, an antigen, a clotting factor, an enzyme, a hormone or a hormone variant, a receptor or portions thereof, a regulatory protein, a structural protein, a reporter, or a transport protein.

In a more preferred embodiment, the enzyme is an 15 oxidoreductase, transferase, hydrolase, lyase, isomerase, or ligase.

In an even more preferred embodiment, the enzyme is an aminopeptidase, amylase, carbohydراse, carboxypeptidase, catalase, cellulase, chitinase, cutinase, deoxyribonuclease, 20 dextranase, esterase, alpha-galactosidase, beta-galactosidase, glucoamylase, alpha-glucosidase, beta-glucosidase, haloperoxidase, invertase, laccase, lipase, mannosidase, mutanase, oxidase, pectinolytic enzyme, peroxidase, phytase, polyphenoloxidase, proteolytic enzyme, ribonuclease, 25 transglutaminase, or xylanase.

In another even more preferred embodiment, the polypeptide is human insulin or an analog thereof, human growth hormone, erythropoietin, or insulinotropin.

The nucleic acid sequence encoding a heterologous 30 polypeptide may be obtained from any prokaryotic, eukaryotic, or other source. For purposes of the present invention, the term "obtained from" as used herein in connection with a given source shall mean that the polypeptide is produced by the

source or by a cell in which a gene from the source has been inserted.

In the methods of the present invention, the mutant filamentous fungal cells may also be used for the recombinant production of polypeptides, which are native to the cell. The native polypeptides may be recombinantly produced by, e.g., placing a gene encoding the polypeptide under the control of a different promoter to enhance expression of the polypeptide, to expedite export of a native polypeptide of interest outside the cell by use of a signal sequence, and to increase the copy number of a gene encoding the polypeptide normally produced by the cell. The present invention also encompasses, within the scope of the term "heterologous polypeptide", such recombinant production of polypeptides native to the cell, to the extent that such expression involves the use of genetic elements not native to the cell, or use of native elements which have been manipulated to function in a manner that do not normally occur in the filamentous fungal cell. The techniques used to isolate or clone a nucleic acid sequence encoding a heterologous polypeptide are known in the art and include isolation from genomic DNA, preparation from cDNA, or a combination thereof. The cloning of the nucleic acid sequences from such genomic DNA can be effected, e.g., by using the well known polymerase chain reaction (PCR), see, for example, Innis et al., 1990, *PCR Protocols: A Guide to Methods and Application*, Academic Press, New York. The cloning procedures may involve excision and isolation of a desired nucleic acid fragment comprising the nucleic acid sequence encoding the polypeptide, insertion of the fragment into a vector molecule, and incorporation of the recombinant vector into the mutant fungal cell where multiple copies or clones of the nucleic acid sequence will be replicated. The nucleic acid sequence may be of genomic, cDNA, RNA, semisynthetic, synthetic origin, or any combinations thereof.

In the methods of the present invention, heterologous polypeptides may also include fused or hybrid polypeptides in which another polypeptide is fused at the N-terminus or the C-terminus of the polypeptide or fragment thereof. A fused 5 polypeptide is produced by fusing a nucleic acid sequence (or a portion thereof) encoding one polypeptide to a nucleic acid sequence (or a portion thereof) encoding another polypeptide. Techniques for producing fusion polypeptides are known in the art, and include, ligating the coding sequences encoding the 10 polypeptides so that they are in frame and expression of the fused polypeptide is under control of the same promoter(s) and terminator. The hybrid polypeptides may comprise a combination of partial or complete polypeptide sequences obtained from at least two different polypeptides wherein one or more may be 15 heterologous to the mutant fungal cell. An isolated nucleic acid sequence encoding a heterologous polypeptide of interest may be manipulated in a variety of ways to provide for expression of the polypeptide. Expression will be understood to include any step involved in the production of the 20 polypeptide including, but not limited to, transcription, post-transcriptional modification, translation, post-translational modification, and secretion. Manipulation of the nucleic acid sequence encoding a polypeptide prior to its insertion into a vector may be desirable or necessary depending on the 25 expression vector. The techniques for modifying nucleic acid sequences utilizing cloning methods are well known in the art.

The present invention is further described by the following examples, which should not be construed as limiting the scope of the invention.

EXAMPLES**Materials**

Chemicals used as buffers and substrates were commercial products of at least reagent grade.

Strains

AB4.1: a strain of *Aspergillus niger* which is a *cspA1 pyrG1* derivative of strain ATTC 9029 (van Hartingsveldt, W., et al., 10 1987. Mol. Gen. Genet. 206:71-75; Bos, C.J., et al., Curr. Genet. 14:437-443)

AB1.13: a protease deficient strain of *Aspergillus niger* derived from UV mutagenesis of AB4.1 (Mattern, I.E., et al., 1992. Mol. Gen. Genet. 234:332-336)

15 13PAP2: an AB1.13 derivative containing multiple copies of the *A. nidulans amdS* gene (Corrick, R. A., et al, 1987. Gene 53: 63 - 71) under control of the *pepA* promoter of *A. niger* (Jarai G. and Buxton F. 1994. Curr Genet 26:238-244). The strain has a protease deficient phenotype and is unable to grow 20 on medium containing acetamide as the sole nitrogen source. Strain 13PAP2 has been deposited at DSM under the name DSM No. 12298.

4PAP6: an AB4.1 derivative containing multiple copies of the of *A. nidulans amdS* gene under control of the *pepA* promoter of 25 *A. niger*. The strain does not have a protease deficient phenotype and is able to grow on medium containing acetamide as the sole nitrogen source.

N402: a strain of *Aspergillus niger*, deposited at the ATCC (Manassas VA, USA) as ATCC Number: 64974

30 MC1046: a strain of *E. coli*, deposited at the ATCC as ATCC Number: 35467

A. oryzae IFO4177: available from Institute for Fermentation, Osaka; 17-25 Juso Hammachi 2-Chome Yodogawa-Ku, Osaka, Japan.

HowB101: described in WO 97/35956.

Plasmids

pPAP: constructed as described below in Example 1 and
5 shown in Figure 1

pAopyrGcosArp1: constructed as described below in Exam-
ple 1 and shown in Figure 2

PEES1: constructed as described below in Example 1 and
shown in Figure 3

10 p3SR2: contains the *A. nidulans* *amdS* gene as described by
C.M. Corrick, A.P. Twomey, and M.J. Hynes (1987. Gene 53: 63-
71)

pABPYRG*-Not: contains an inactivated *pyrG* gene as
described by Verdoes, J.C., et al. (1994. Gene 145: 179-187)

15 pHapl: contains the *pyrG* gene from *A. oryzae* as a selec-
tive marker and the *AMA1* sequences which enable autonomous rep-
lication in *A. niger*, cloned into the *E. coli* vector pIC20R, as
described by Gems, D., et al. (1991. Gene 98: 61-67)

20 pAnsco1: contains two *cos* sites as described by
Osiewacz, H.D. (1994. Curr. Genet. 26: 87-90)

pAO4-2: contains the *A. oryzae* *pyrG* gene as described by De
Ruiter-Jacobs, Y.M.J.T., et al. (1989. Curr. Genet. 16: 159-
163)

25 pAO4-13: contains the *A. oryzae* *pyrG* gene as described by De
Ruiter-Jacobs, Y.M.J.T., et al. (1989. Curr. Genet. 16:159-
163)

pUC19: as described by Yanisch-Perron, C., Vieira, J. and
Messig, J. (1985, Gene 33:103-119)

pDV8: described in Example 8 and shown in Fig. 7.

30 pJaL554: described in Example 8 and shown in Fig. 8

Deposit of Biological Materials

The following biological material has been deposited under
the terms of the Budapest Treaty with the Deutsche Sammlung von

Microorganismen und Zellkulturen GmbH, Mascheroder Weg 1b, D-38124 Braunschweig, Germany and given the following accession number:

Deposit	Accession Number	Date of Deposit
5 <i>Escherichia coli</i> , pEES	DSM 12294	1998-07-14
<i>Aspergillus niger</i> 13PAP2	DSM 12298	1998-07-14

The strain has been deposited under conditions that assure that access to the culture will be available during the 10 pendency of this patent application. The deposit represents a substantially pure culture of the deposited strain. The deposit is available as required by foreign patent laws in countries wherein counterparts of the subject application, or its progeny are filed. However, it should be understood that 15 the availability of a deposit does not constitute a license to practice the subject invention in derogation of patent rights granted by governmental action.

EXAMPLES

20

Example 1

Cloning of the *A. niger* *prtT* transcriptional activator

The *prtT* gene was cloned from 13PAP2, an *A. niger* mutant strain which is unable to express the *amdS* gene regulated by the *pepA* 25 protease gene promoter and has a protease deficient phenotype (*prt⁻*).

Construction of the *A. niger* 13PAP2 reporter strain

The plasmid pPA1 was constructed by ligation of the following 30 three fragments:

- 1) the *E. coli* vector pBlueScript II SK (Stratagene Cloning Systems, La Jolla CA, USA) digested with EcoRI and KpnI;
- 2) a 1.4 kb EcoRI/BamHI restriction fragment containing the 1.2 kb promoter region of the *pepA* gene linked to about

- 130 bp of the *amdS* coding sequence from the start codon to an internal BamHI site, amplified by PCR; and
3) a 2.1 kb BamHI/KpnI fragment from p3SR2 which contains most of the *A. nidulans* *amdS* gene

5

Fragment 2 was constructed in two steps. In a first step genomic DNA from *A. niger* N402 prepared from protoplasts as described below in the section "Construction of the Cosmid Library" was used as the template, and the two oligonucleotides shown below, pepApr and pepA/amdS, were used as primers:

PepApr: CGG AAT TCG CAT GCT GGA GGT GCT TCT AA (SEQ ID NO: 6)

pepA/amdS:TTC CCA GGA TTG AGG CAT TTT GAC CAC GAG AAT (SEQ ID NO:

15

The 1200 bp PCR product obtained from this reaction was then used as a primer in a second PCR reaction together with the oligonucleotide MBL1213 shown below, and plasmid p3SR2 as the template.

20

MBL1213: TAA CTT CCA CCG AGG TC (SEQ ID NO: 8)

The product obtained by ligation of the three fragments described above was subsequently transfected into *E. coli* DH5 α .

25 In the final construction procedure, pPA1 was digested with NotI and ligated to a 3.8 kb NotI fragment from pABPYRG*-Not, resulting in plasmid pPAP which is shown in Fig. 1. pPAP was transformed into *A. niger* AB 1.13, and a transformant with pPAP integrated into the *pyrG* locus in multicopy was isolated. A 30 spontaneous 5 fluorotic acid (FOA) resistant, uridine-requiring mutant of this transformant that could be complemented with the *pyrG* gene was named 13PAP2.

Construction of pAopyrGcosArp1

The plasmid pAopyrGcosArp1 was constructed by ligation and subsequent transfection into *E. coli* DH5 α of the following three fragments:

- 5 1) the *E. coli* vector pHelp1 cut with Acc65I and BamHI
- 2) a 3.0 kb BamHI/HindIII fragment from pAnsCos1 containing two cos sites
- 3) a 3.2 kb Acc65I/HindIII fragment from pAO4-2 containing the *A. oryzae* pyrG gene

10

The resulting plasmid, pAopyrGcosArp1, is self-replicating in *Aspergilli* and can be selected for by growth on medium lacking uridine. pAopyrGcosArp1 is depicted in Fig. 2.

15 Construction of the cosmid library.

A cosmid library of *Aspergillus niger* was constructed using the "SuperCos1 cosmid vector kit" (Stratagene Cloning Systems, La Jolla CA, USA) according to the supplier's instructions.

Genomic DNA from *A. niger* N402 was prepared from protoplasts
20 made by standard procedures.

After isolation the protoplasts were pelleted by centrifugation at 2000 rpm for 10 minutes in a Beckman GS-6R; the pellet was then suspended in a buffer containing 22.5 mM tris(isonaphthalene sulphonic acid), 275 mM para-aminosalicylic acid,
25 0.2 M Tris-HCl (pH 8.5), 0.25 M NaCl and 50 mM EDTA immediately followed by addition of 1 volume of phenol/chloroform (1:1). After careful mixing and centrifugation at 3000 rpm for 20 minutes the aqueous phase was decanted and DNA was precipitated using standard procedures.

30 The size of the genomic DNA was analysed by electrophoresis on a 0.3% agarose gel run for 20 hours at 30 volts at 4°C. The ethidium bromide stained gel showed that the recovered DNA ranged in size from 50 to greater than 100 kb. The DNA was partially digested using MboI. The size of the digested DNA was

30 to 50 kb as determined by the same type of gel analysis as above. The pAopyrGcosArp1 vector, purified using a kit from QIAGEN (Venlo, The Netherlands) following the manufacturer's instructions, was digested with BamHI, dephosphorylated and gel 5 purified. Ligation and packaging were performed following standard procedures.

After titration of the library, all of the packaging mix from a single ligation and packaging was transfected into the host cell, MC1046, and plated on 50 µg/ml ampicillin LB plates. 10 Approximately 40,000 colonies were obtained. Cosmid preparations from 10 colonies showed that they all had inserts of the expected size. The 40,000 colonies were then soaked in LB medium and scraped off of the plates, then aliquoted for storage in 15% glycerol at -80°C. This represents an approximate 40-15 fold amplification of the *A. niger* genome.

Selection of *A. niger* *prtT* clones

Cosmid DNA was prepared from the library and introduced into 13PAP2 according to the transformation procedure described by 20 P.J. Punt and C.A.M.J.J. Van Den Hondel (1992. *Methods Enzymol* 216: 447-457). Repeated efforts to select for the *pyrG* marker only resulted in a recovery of between 4000 to 30,000 transformants. A double selection for the *pyrG* marker and growth on 25 medium containing acetamide as the sole nitrogen source resulted in a total of 65 primary transformants from five different experiments.

Each primary transformant was screened for protease activity, growth on medium containing acetamide as the sole nitrogen source and instability of the these two characteristics. An 30 acetamidase⁺ phenotype, screened by growth on medium containing acetamide, is an indication of acetamidase activity resulting from activation of the *pepA* promoter in the reporter cassette in which the *pepA* promoter is linked to the *amdS* coding sequence. A protease⁺ phenotype was screened using minimal me-

dium plates containing dialyzed skim milk as the sole nitrogen source (Mattern, I.E., et al., 1992. Mol Gen Genet 234:332-336). On these plates the wild-type AB4.1 strain makes a clear halo whereas the AB1.13 mutant produces a very small halo. This difference is not due to differences in the activity of *pepA*, since a *pepA* deleted strain can also produce a large halo on these plates. Therefore, a large halo on milk plates indicates activation of other extracellular proteases.

Instability was tested by growing diluted spore stocks on a medium containing uridine. Single-spore-derived colonies were picked from these plates and tested for protease activity and growth on acetamide. The screening results revealed that in more than 70% of the colonies both characteristics were lost. Therefore, the two phenotypes were either lost or retained together, indicating that activation of the *pepA* promoter and other protease promoters is coordinately regulated and linked to the presence of the *pyrG* marker. The gene responsible for this phenotype was named *prtT*. Twelve acetamidase⁺, protease⁺ transformants were then isolated.

20

Isolation of the *A. niger* *prtT* gene

In order to rescue the *prtT* gene from the acetamidase⁺, protease⁺ transformants of 13PAP2, DNA was prepared from mycelium grown in minimal medium as previously described. This DNA was used in an attempt to transform competent *E. coli* DH5 α cells. Several hundreds of ampicillin-resistant colonies were obtained. DNA analysis showed they all contained sequences derived from the pHelp1 plasmid. Cosmid DNA isolated from *E. coli* colonies was then retransformed into 13PAP2. Two DNA samples gave rise to transformants, which showed both growths on acetamide containing medium and increased protease activity. DNA from one of the cosmids, ACR1, was then digested with several restriction enzymes. The resulting fragments were then co-transformed with pAopyrGcosArp1 into strain 13PAP2. EcoRI,

PstI, BamHI and KpnI digestion of ACR1 gave rise to transformants capable of growth on acetamide and high protease activity, whereas SalI and HindIII digests did not. Because EcoRI digestion gave the simplest pattern, separate EcoRI fragments were gel-isolated and with pAopyrGcosArp1 used to co-transform 13PAP2. Only one fragment, a 15 kb EcoRI fragment, gave rise to transformants capable of growth on acetamide-containing medium. This fragment was subcloned in pBluescript II SK in order to subclone *prtT* from the cosmid. Since the insert of this clone was still rather large, separate PstI bands were gel isolated and each was co-transformed with pAopyrGcosArp1 into 13PAP2. Only one band, a 2.5 kb PstI fragment, gave rise to transformants that could grow on acetamide-containing medium. This fragment was subcloned in pBlueScript II SK. Four sub-clones, CLE 0.7, CLE 1.8, NcE 1.1 and NcE 1.4, were constructed from this plasmid based on the restriction map. In addition, a 6.5 kb SstI/EcoRI fragment encompassing the 2.5 kb PstI fragment was subcloned, resulting in pEES1 (shown in Fig. 3).

Southern blot analysis of genomic DNA from AB4.1 showed the presence of only one copy of *prtT*.

Example 2

Sequencing of the *A. niger* *prtT* gene and analysis of the sequence

All sequence reactions were prepared using dRhodamine Terminator Cycle Sequencing Kits or BigDye™ Terminator Cycle Sequencing Kits from the Perkin-Elmer Corporation (Branchburg NJ, USA). The reactions were run on an ABI PRISM® 377 DNA Sequencer (Perkin-Elmer Corporation) following the manufacturer's instructions.

The *prtT* gene was sequenced from the genomic clones CLE 0.7, CLE 1.8, NcE 1.1, NcE 1.4 and pEES1. The sequence specific primers used are listed below:

122958: CGA TCG ATG ACT GCC TGT (SEQ ID NO: 9)

50

122956: AGA GAC ACA TAG TGC CTT (SEQ ID NO: 10)
122959: GCT TAT AGT CGA TAG CGC (SEQ ID NO: 11)
122960: CCT CTC TCC AGC GAT GGT (SEQ ID NO: 12)
122962: ATG GAA TAC ATA CTG CTT (SEQ ID NO: 13)
5 122961: ATG AAA CCC ACT GTA GCT (SEQ ID NO: 14)
122963: TGC TCG ATA AGC GGG TCC (SEQ ID NO: 15)
122964: AAT CTT ATG GAC CCG CTT (SEQ ID NO: 16)
124289: CCC CGG GAA ACA AGA ACA GG (SEQ ID NO: 17)
124290: GTT GGC GGA CCT TGA CTA TG (SEQ ID NO: 18)
10 125112: ACA GCT ACA GTG GGT TTC ATC T (SEQ ID NO: 19)
125111: AGT CAA CGG GGG AAG TCT C (SEQ ID NO: 20)
128330: CTA GCA GCG TAT CGG TCA GC (SEQ ID NO: 21)
130887: CTT GGA AAA GAA ACG ATA G (SEQ ID NO: 22)
130888: AAC GTA CGC TTT CCT CCT T (SEQ ID NO: 23)
15 134135: GGG TCC GTC CAG TCC GTT CTT (SEQ ID NO: 24)

-48 reverse: AGC GGA TAA CAA TTT CAC ACA GGA (SEQ ID NO:
25)

-40 universal: GTT TTC CCA GTC ACG AC (SEQ ID NO: 26)

20

A mutant allele of the gene was obtained by PCR amplification of genomic DNA isolated from the mutant strain AB1.13 using the following primers:

25 PstI: TC ATC CCT GGT GTT ACT GC (SEQ ID NO: 27)
PstII: C ATG GAT TGG CTG GCC G (SEQ ID NO: 28)

The complete DNA sequence of the *prtT* gene is shown in SEQ ID NO:1. The sequence of the PCR fragment of the mutant allele 30 is shown in SEQ ID NO:4.

Analysing the DNA sequence SEQ ID NO:1 using the computer software Netgene 2 (S.M. Hebsgaard, P.G. Korning, N. Tolstrup, J. Engelbrecht, P. Rouze, S. Brunak (1996. Nucleic Acids Re-

search 24: 3439-3452) suggested the existence of 5 exons (see annotations to SEQ ID NO 1).

Analysis of the *A. niger* prtt cDNA

5 mRNA was purified from total RNA (isolated according to the DNA isolation method described above in Example 1) using a commercial poly(A)⁺ RNA isolation kit (Pharmacia, Uppsala SE) from a culture of *A. niger* grown under conditions favourable for protease production (J.P.T.W. Van Den Hombergh, et al., 1997.
10 Eur. J. Biochem. 247:605-613). Double stranded cDNA was prepared using standard procedures and used for PCR reactions with the following primers:

oligo-dT primer: T₂₀N

15 Prt270n: TACTCTCCAGATTGCCTG (SEQ ID NO: 29)
Prt1420r: TGAGATAACCACTCAGCAG (SEQ ID NO: 30)
prt1350n: TGCACTTCTCTGTCTCTG (SEQ ID NO: 31)
Prt2365r: GACTTCTGGCATCAGTTG (SEQ ID NO: 32)
prt2320n: CTCATGGATGGCATGATC (SEQ ID NO: 33)

20

A PCR reaction with the primers Prt270n and Prt1420r produced a fragment of approximately 1.0 kb. The fragment was cloned into a pGEM-T vector (Promega Corp., Madison WI, USA), and the insert in the resulting plasmid was sequenced using the
25 primers 122958, 122960, -40 universal and -48 reverse. The result confirmed the presence of two introns in this part of the gene.

A second PCR reaction with the primers Prt1350n and Prt2365r produced a fragment of approximately 0.9 kb. This fragment was
30 also cloned in a pGEM-T vector, and the insert in the resulting plasmid was sequenced using the primers 124289, 124290, -40 universal and -48 reverse. The result confirmed the presence of a single intron in this part of the gene.

Another PCR reaction with the oligo-dT primer and primer Prt2320n produced a fragment of approximately 350 bp. This fragment was also cloned in a pGEM-T vector. Sequencing of the insert using primers -40 universal and -48 reverse showed that 5 the fragment contained the 3' part of *prtT* and confirmed the presence of another intron.

The deduced protein sequence of the translated *prtT* gene is shown in SEQ ID NO:2. The deduced protein sequence of the translated mutant allele *prt13* is shown in SEQ ID NO:5. A comparison 10 of SEQ ID NO:2 and SEQ ID NO:5 indicates that the only difference between the two is in position 112 where the leucine residue in the translated *prtT* gene is replaced by proline in the translated *prt13* gene.

Analysis of the deduced PrtT protein sequence reveals the 15 presence of a Zinc(II)2Cys6 binuclear cluster DNA binding motif (SEQ ID NO:2, residues 47-81). This motif defines the GAL4 class of fungal transcriptional activators (Reece, M. J., and Ptashne, M. 1993. Science 261: 909-911). The presence of the motif in the *prtT* gene strongly indicates that *prtT* is a trans- 20 scriptional activator.

EXAMPLE 3:

Disruption of the *prtT* gene in a wild-type *A. niger* strain

A plasmid was constructed in which the upstream and downstream 25 sequences of the *prtT* gene are separated by the *A. oryzae* *pyrG* gene. Plasmid pEES1 was digested with MunI and NheI, which removed a 2.1 kb fragment containing most of the coding sequence of *prtT*. A 2.3 kb EcoRI/NheI fragment from pAO4-13 containing the *A. oryzae* *pyrG* gene was cloned in the 30 MunI and NheI sites of pEES1. The resulting plasmid, shown in Fig. 4, was named pDprt. This construct was then used to transform *A. niger* strain AB4.1 to uridine prototrophy. About 150 uridine prototrophic transformants were then analyzed for protease activity on skim milk containing plates. Five of

these did not make a halo on these plates indicating that protease activity was very low. Comparison of strains with a disrupted *prtT* gene and the mutant AB1.13 strain did not show any differences in protease activity or phenotype.

5

Example 4**Overexpression of *A. niger* *PrtT***

- A plasmid, pGPprt, (Figure 5) containing the coding region 10 and 3' noncoding sequences of *prtT* fused to the promoter of the *A. niger* *gpd* gene was constructed. The *gpd* gene codes for glyceraldehyde-3-phosphate dehydrogenase and a constitutively expressed enzyme involved in primary metabolism. The promoter used was a fragment upstream of the coding region.
- 15 The plasmid is transformed into *A. niger* AB4.1 by cotransformation with the *pyrG* selection plasmid pAO4-13. Transformants with increased *prtT* transcription as determined by Southern blot analysis is analysed for increased protease expression.

20 Example 5**Isolation of the Zn²⁺-finger from the *A. oryzae* *prtT* gene**

The *A. niger* *prtT* gene is shown in SEQ ID NO: 1. The protein sequence deduced from the DNA sequence of *prtT* (SEQ ID NO: 2) contains a so called Zn²⁺-finger motif expected to be 25 responsible for the DNA binding of the transcriptional activator encoded by *prtT*. The Zn²⁺-finger motif has the following amino acid sequence: Met Thr Ala Cys His Thr Cys Arg Lys Leu Lys Thr Arg Cys Asp Leu Asp Pro Arg Gly His Ala Cys Arg Arg Cys Leu Ser Leu Arg Ile Asp Cys (SEQ ID NO: 34).

30 Degenerate primers able to code for amino acid sequences from the motif were designed and synthesized by DNA Technology A/S, Forskerparken, Gustav Wieds vej 10, DK-8000 Aarhus C, Denmark. The primers had the following sequences:

137396: A T G A C C/T G C C/T T G C/T C A C/T A C C/T T G (SEQ ID NO: 35)

137397: A A/G A/G C A A/G/C/T C G A/G/C/T C G A/G C A A/G G C A/G T G (SEQ ID NO: 36)

5 The primers were used in a PCR reaction with genomic *A. oryzae* IFO4177 DNA as template. The reaction was performed in a total volume of 100 μ l containing 154 pmol of primer 137396 and 10164 pmol of primer 137397. 30 PCR cycles with 56°C as annealing temperature and 30 seconds elongation time were run. An-
10 other PCR reaction using *A. niger* genomic DNA and the primers
137394: ATGACTGCCTGTCACACATG (SEQ ID NO: 37)
and 137395: AGACAGCGACGGCACGCATG (SEQ ID NO: 38), which are specific for the *A. niger* *prtT* gene, was also run. In this re-
action 10 pmol of each primers was used in a 100 μ l reaction.
15 Aliquots of the two reactions were applied to a 3% agarose gel. After electrophoresis three approximately equally intense bands could be seen in the *A. oryzae* reaction and two bands in the *A. niger* reaction. One of the bands in the *A. niger* reaction was more intense than the other and further had the expected size.
20 One of the *A. oryzae* bands had the same size as the most intense *A. niger* band and was isolated from the gel. The fragment was cloned into the vector pCR2.1 (Invitrogen™). Plasmids from two individual colonies were sequenced. The sequences are shown in figure 1. The two sequences differ at the end reflecting
25 their origin in different degenerate primers. They are identi-
cal in the middle 40bp, which are amplified from the genomic DNA. These 40 basepairs encode a polypeptide identical to a part of the Zn²⁺-finger of the *A. niger* *prtT* gene.

30 **Example 6**

Isolation of the N-terminal of the *A. oryzae* *prtT* gene

The inverse PCR method was used to isolate the *A. oryzae* *prtT* gene. The primers 144428: CACCGAGTTTAAGCTTGCGG (SEQ ID NO: 39) and 144429: GCGATCTTGATCCACGAGGG (SEQ ID NO: 40) were

synthesized by DNA Technology A/S (Denmark). Genomic DNA was cut with a number of restriction enzymes and religated. The ligation mixtures were used as templates in PCR reactions with the primers 144428/144429. In a reaction with *BamHI* restricted 5 and religated DNA as template a fragment of approximately 2.5kb was observed after electrophoresis on an agarose gel. The fragment was labelled with ^{32}P by the random priming method and used as a probe against a filter containing a gridded cosmid library of genomic *A. oryzae* DNA. The construction of the library is described in WO 98/01470. The cosmid 11F8 showed a positive hybridization signal with the probe. A Southern blot containing DNA from 11F8 and genomic DNA restricted with *BamHI*, *EcoRI*, *PstI* or *XhoI* was probed with the 2.5kb inverse PCR fragment. The size of hybridizing bands from genomic DNA were compared with those from the cosmid DNA. Apparently some rearrangement of the cosmid had occurred since only a minority of the bands from the genomic DNA had counterparts in the cosmid. Two hybridizing fragments from the cosmid, a 1.2 kb *EcoRI* fragment and a 1.0 kb *PstI* fragment, looked equal in size to hybridizing genomic fragments. The two fragments were sub-cloned 20 from the cosmid and sequenced. Analysis of the sequence data showed that the fragments overlap. In total 1497 bp of sequence was obtained. Oligonucleotides encoding the Zn^{2+} -finger were not contained within the sequence. A *BamHI* site was found close 25 to one end of the sequence in a region only covered by the *EcoRI* sub-clone, thus allowing the position of the sequenced genomic fragment relative to the Zn^{2+} -finger to be determined. The primer 153468: CGGGATGAATTGTAGAGAGGC (SEQ ID NO: 41) was prepared by DNA Technology A/S (Denmark). The primer sequence 30 is contained within the 1497 bp fragment. It is found at the end closest to the Zn^{2+} -finger and points in that direction. Two primers both of *prtT* Zn^{2+} -finger specific sequence and pointing either downstream (140358) or upstream (140359) were also prepared by DNA Technology A/S (Denmark). The sequence of

the two primers are as follows: 140358:
CGCAAAGCTTAAACTCGGTGCGATC (SEQ ID NO: 42) and 140359:
CCTCGTGGATCAAGATCGCA (SEQ ID NO: 43). Two PCR reactions, one
with the primers 153468 and 140358 and one with 153468 and
140359, respectively, were performed with genomic DNA as tem-
plate. The reaction with 153468 and 140359 gave a band of ap-
proximately 1.1 kb, the other reaction gave no visible bands,
when analysed on an agarose gel. The 1.1 kb fragment was cloned
into pCR4Blunt-TOPO (Invitrogen) and sequenced. The fragment
10 contained part of the Zn²⁺-finger and overlaps with the 1497bp
fragment. Translation of the sequence showed that the region
immediately upstream of the Zn²⁺-finger encodes a polypeptide
with homology to the N-terminal of *prtT* from *A. niger*.

15 Example 7

Isolation of the complete *A. oryzae* *prtT* gene

The remaining parts of the gene were cloned by two con-
secutive rounds of inverse PCR. In the first inverse PCR reac-
tion the genomic DNA was restricted with *EcoRV* and re-ligated.
20 The PCR reaction was run with the primers 175653:
GATGAAAAGATAATCGGCGAG (SEQ ID NO: 44) and 175654:
CGCGGCACACTACCCCCGTTG (SEQ ID NO: 45). The reaction resulted in
the synthesis of a 1.9kb fragment, which was cloned into the
pCR4Blunt-TOPO vector and sequenced. Analysis of the sequence
25 data showed that the fragment contains a gene with homology to
the *A. niger* *prtT* gene and that the 3'end of the gene was miss-
ing. The second inverse PCR reaction was thus performed. The
primers were B0403G08: ATCTAGCTCAAGCATTAGCGGC (SEQ ID NO: 46)
and B0403G09: AATTCGGCCCTTAGTGTCC (SEQ ID NO: 47). *BglII* re-
30 stricted and re-ligated genomic DNA was used as template. A 2.4
kb fragment was obtained and cloned into the pCR4Blunt-TOPO
vector and sequenced. Analysis of the sequence showed that the
complete *A. oryzae* *prtT* gene had been obtained. The DNA se-
quence of the *A. oryzae* *prtT* gene is shown in SEQ ID NO: 48

and the deduced amino acid sequence of the encoded protein is shown in SEQ ID NO: 49.

Example 8

5 Disruption of the *Aspergillus oryzae* *prtT* gene.

The *A. oryzae* *prtT* gene was disrupted using a method of positive/negative selection. A disruption cassette consisting of 2kb of the *A. oryzae* *prtT* gene (SEQ ID NO: 48) with an insertion of the *pyrG* gene in the middle is cloned into a vector 10 (pDV8) containing the herpes simplex virus I thymidine kinase gene (HSV-tk) flanked by fungal expression signals. Expression of the thymidine kinase gene makes the host sensitive to 5-fluoro-2-deoxyuridine. A disrupted strain can be isolated by positive selection for the *pyrG* gene in a *pyrG* minus host and 15 deselection of the thymidine kinase gene on 5-fluoro-2-deoxyuridine. Since the thymidine kinase gene and the *pyrG* gene are present in the same DNA fragment selection is for transformants in which a double cross-over event has happened. The system gives fewer transformants per. Micro g of DNA than transformation with just a disruption cassette, but the frequency of transformants in which the desired homologous recombination event has occurred is much higher.

The *pyrG* gene used here is flanked by repeats enabling a later removal by selection for 5-fluoroorotic acid resistance. The 25 *pyrG* gene is isolated from the plasmid pJaL554.

The pDV8 plasmid:

pDV8 was kindly provided by Matthew S. Sachs, University of Oregon, PO Box 91000, Portland, OR 97291-1000, USA. pDV8 30 (Fig. 7) is a PSP65 (Promega™) based plasmid containing the HSV-tk gene on a 1.2 kb *Bgl*II/*Bam*HI fragment inserted between a 1.0 kb *Xho*I/*Bgl*II fragment of the *A. nidulans* *gpd* promoter and a 0.8 kb *Bam*HI/*Hind*III fragment containing the *A. nidulans* *trpC* transcriptional terminator.

The *A. nidulans* *gpd* promoter and the *trpC* transcriptional terminator are taken from the plasmid pAN51-2 (Punt et al., (1990), Gene 93, p.101-109). The HSV-tk gene is described by McKnight S.L., (1980), Nucleic Acids Res. 8:5949-5964, Database 5 accession no. EMBL v00470, position 252-1479. The construction of pDV8 is described in Vaught-Alexander D (thesis) Expression of the herpes simplex virus type-1 thymidine kinase gene in *Neurospora crassa*, (1994), Oregon Graduate Institute of Science & Technology, University of Portland, PO Box 91000, Portland, OR 97291-1000, USA. The sequence of pDV8 is included in this application as SEQ ID NO: 50. Single-, double- and multi-copy *A. oryzae* transformants of pDV8 were isolated by transforming a pDV8 derivative containing the *A. oryzae niaD* gene into an *A. oryzae niaD* mutant. The copy number of the HSV-tk 10 gene was determined by Southern analysis. The transformants and the untransformed host were inoculated onto plates containing varying concentrations of 5-fluoro-2'-deoxyuridine. From inspection of the growth on the plates it was decided to use 6 microM of 5-fluoro-2'-deoxyuridine in the plates for future 15 positive/negative selection experiments. At this concentration none of the pDV8 transformants grew, while the untransformed host was only slightly inhibited.

Description of pJaL554:

25 PJaL554 was constructed by ligating the 316 bp *Asp718-NheI* fragment to the 5336 bp *SpeI-SspBI* fragment from the *pyrG* containing plasmid pSO2 (described in WO 97/35956). Thus, pJaL554 harbours the *A. oryzae pyrG* gene flanked by 316 bp repeats. The construction is illustrated in Fig. 8.

30

Construction of a *prtT* disruption plasmid in the pDV8 vector:

A PCR reaction is performed on chromosomal *A. oryzae* IFO4177 DNA with the primers B1042E05 and B1450E07.
B1042E05: CGCGCGTATCCTATTGCC (SEQ ID NO: 51)

B1450E07: GCCGGAAATGTTGTACCTAC (SEQ ID NO: 52).

A fragment of 2078 basepairs is obtained and cloned into the pCR4Blunt-TOPO (Invitrogen™) vector. The resulting plasmid is sequenced with the standard M13 forward (-40) and reverse primers to ensure that the correct fragment is obtained. The PCR fragment is excised from the vector by the restriction enzyme *EcoRV* which cuts twice internally in the fragment. The cut sites are located at positions 1 and 1964 in SEQ ID NO: 48. The 1964 bp fragment is ligated with the pDV8 vector, which has been cut with *HindIII* and blunt ended by filling in the ends with the Klenow fragment of DNA polymerase I from *E. coli* and dNTP. The resulting plasmid is cut with *HindIII*, which is located in the *prtT* fragment (in the part encoding the Zn²⁺-finger) at position 962 in SEQ ID NO: 48, dephosphorylated and ligated with the *pyrG* gene isolated from pJaL554 as a 2.5 kb *HindIII* fragment.

Selection of *prtT* disrupted strains:

The disruption plasmid described above was linearized with *NotI* and transformed into *A. oryzae* HowB101 (described in WO 97/35956), a *pyrG* minus derivative of IFO4177. The transformation is done essential as described in EP 0 238 023. Transformants are selected on plates containing Coves salt solution (Cove DJ, (1966), Biochim. Biophys. Acta 113:51-56), 1 M sucrose for osmotic stabilization and as carbon source, 20g/L agar, 10 mM NaNO₃ and 6 microM 5-fluoro-2-deoxyuridine (Sigma). The transformants are reisolated once on the same type of plates. Transformants carrying a disrupted *prtT* gene are identified by Southern blot analysis.

A strain carrying the *prtT* disruption is used as host for expression of a truncated PDI gene (Protein Disulfide isomerase gene) harbored on the expression plasmid pCaHj445 (described in US patent 5,879,664). pCaHj445 is transformed into the *A. oryzae* *prtT* disrupted strain by cotransformation with the plasmid p3SR2 containing the *A. nidulans* *amdS* gene. Transformation

and selection on acetamide plates is done essentially as described in EP 0 238 023. After reisolation the transformants are fermented in shake flasks or fermentors and the PDI protein is purified from the fermentation broth.

5

The invention described and claimed herein is not to be limited in scope by the specific embodiments herein disclosed, since these embodiments are intended as illustrations of several aspects of the invention. Any equivalent embodiments 10 are intended to be within the scope of this invention. Indeed, various modifications of the invention in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description. Such modifications are also intended to fall within the scope of the 15 appended claims.

Various references are cited herein, the disclosures of which are incorporated by reference in their entireties.

0-1	Form - PCT/RO/134 (EASY) Indications Relating to Deposited Microorganism(s) or Other Biological Material (PCT Rule 13bis)		
0-1-1	Prepared using		PCT-EASY Version 2.91 (updated 01.01.2001)
0-2	International Application No.		PCT/DK01/00169
0-3	Applicant's or agent's file reference		10023-WO
1	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:		
1-1	page	44	
1-2	line	4-6	
1-3	Identification of Deposit		
1-3-1	Name of depositary institution		
1-3-2	Address of depositary institution		
1-3-3	Date of deposit		
1-3-4	Accession Number		
1-4	Additional Indications		
1-5	Designated States for Which Indications are Made		
1-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later		
2	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:		
2-1	page	44	
2-2	line	4-6	
2-3	Identification of Deposit		
2-3-1	Name of depositary institution		
2-3-2	Address of depositary institution		
2-3-3	Date of deposit		
2-3-4	Accession Number		
2-4	Additional Indications		
2-5	Designated States for Which Indications are Made		
2-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later		

Claims:

1. An isolated nucleic acid sequence encoding a polypeptide having transcriptional activation activity, selected from 5 the group consisting of:
 - (a) a nucleic acid sequence having at least 70% identity with the nucleic acid sequence of SEQ ID NO:1 or SEQ ID NO: 48;
 - (b) a nucleic acid sequence encoding a polypeptide 10 having an amino acid sequence which has at least 50% identity with the amino acid sequence of SEQ ID NO:2 or SEQ ID NO: 49;
 - (c) a nucleic acid sequence which hybridizes under low 15 stringency conditions with (i) the nucleic acid sequence of SEQ ID NO:1 or SEQ ID NO: 48, or (ii) its complementary strand, wherein the low stringency conditions are defined by prehybridization and hybridization at 42°C in 5x SSPE, 0.3% SDS, 200 micro g/ml sheared and denatured salmon sperm DNA, and 25% 20 formamide, and wash conditions are defined by 50°C for 30 minutes in 2X SSC, 0.2% SDS;
 - (d) an allelic variant of (a), (b), or (c);
 - (e) a subsequence of (a), (b), (c), or (d), wherein the 25 subsequence encodes a polypeptide fragment which has transcriptional activation activity; and
 - (f) a subsequence of (a), (b), (c), or (d), wherein the subsequence encodes a polypeptide with the amino acid sequence of SEQ ID NO:3.
2. The nucleic acid sequence of claim 1 which has at least 70%, 30 preferably at least 80%, more preferably at least 85%, even more preferably at least 90%, most preferably at least 95%, even most preferably at least 97%, and even more preferred

at least 99% identity with the nucleic acid sequence of SEQ ID NO:1 or SEQ ID NO: 48.

3. The nucleic acid sequence of claim 1 which has the nucleic acid sequence of SEQ ID NO:1 or SEQ ID NO: 48.

4. The nucleic acid sequence of any of claims 1 to 3 which encodes a polypeptide comprising an amino acid sequence which has at least 50%, preferably at least 60%, preferably at least 70%, more preferably at least 80%, even more preferably at least 90%, and most preferably at least 95% identity with the amino acid sequence of SEQ ID NO:2 or SEQ ID NO: 49.

15 5. The nucleic acid sequence of any of claims 1 to 4, wherein the nucleic acid sequence is obtained from a fungal cell or a yeast cell.

20 6. The nucleic acid sequence of claim 5, wherein the fungal cell is a filamentous fungal cell.

7. The nucleic acid sequence of claim 6, wherein the filamentous fungal cell is an *Aspergillus*, *Fusarium*, *Penicillium*, or *Trichoderma* cell.

25

8. The nucleic acid sequence of claim 7, wherein the *Aspergillus* cell is a strain of *Aspergillus niger* or *Aspergillus oryzae*, or a respective synonym or teleomorph thereof.

30

9. The nucleic acid sequence of claim 8, wherein the *Aspergillus* cell is a strain of *Aspergillus niger* DSM 12298 or *Aspergillus oryzae* IFO4177.

10. The nucleic acid sequence of claim 7, wherein the *Fusarium* cell is a strain of *Fusarium venenatum*, or a synonym or teleomorph thereof.
- 5 11. The nucleic acid sequence of claim 5, wherein the yeast cell is a *Hansenula*, *Pichia*, or *Saccharomyces* cell.
12. The nucleic acid sequence of any of claims 1 to 11 which encodes a polypeptide comprising the amino acid sequence of SEQ ID NO:2 or SEQ ID NO: 49, or a fragment thereof, which has transcriptional activation activity.
13. The nucleic acid sequence of any of claims 1 to 11 which encodes a polypeptide comprising the amino acid sequence of SEQ ID NO:3.
14. The nucleic acid sequence of any of claims 1 to 13, which hybridizes under low, preferably medium, and more preferably high, stringency conditions to (i) the nucleic acid sequence set forth in SEQ ID NO:1 or SEQ ID NO: 48 or (ii) the respective complementary strand, or a subsequence thereof.
15. The nucleic acid sequence of claim 14, wherein low stringency conditions are defined by prehybridization and hybridization at 42°C in 5X SSPE, 0.3% SDS, 200 micro g/ml sheared and denatured salmon sperm DNA, and 25% formamide, and wash conditions are defined by 50°C for 30 minutes in 2X SSC, 0.2% SDS; medium stringency conditions are defined by prehybridization and hybridization at 42°C in 5x SSPE, 0.3% SDS, 200 microg/ml sheared and denatured salmon sperm DNA, and 35% formamide, and wash conditions are defined by 60°C for 30 minutes in 2X SSC, 0.2% SDS; and high stringency conditions are defined by prehybridization and hybridization at 42°C in 5x SSPE, 0.3% SDS, 200 microg/ml sheared and

denatured salmon sperm DNA, and 50% formamide, and wash conditions are defined by 70°C for 30 minutes in 2X SSC, 0.2% SDS.

5 16. The nucleic acid sequence of any of claims 1 to 15, which comprises the nucleic acid sequence encoding a polypeptide, which has transcriptional activation activity contained in the plasmid pEES harboured in *Escherichia coli* DSM 12294 or DNA sequence shown in SEQ ID NO: 48 encoding polypeptide 10 shown in SEQ ID NO: 49.

17. A nucleic acid construct comprising the nucleic acid sequence of any of claims 1 to 16 operably linked to one or more control sequences, which direct the production of the 15 polypeptide in a suitable expression host.

18. An expression vector comprising the nucleic acid construct of claim 17, a promoter, and transcriptional and translational stop signals.

20 19. A host cell comprising the nucleic acid construct of claim 17 or the expression vector of claim 18.

25 20. An isolated polypeptide selected from the group consisting of:

(a) a polypeptide which is encoded in a nucleic acid sequence which hybridizes under low stringency conditions with (i) the nucleic acid sequence of SEQ ID NO:1 or SEQ ID NO: 48; (ii) its complementary strand, or (iii) a 30 subsequence of SEQ ID NO:1 or SEQ ID NO: 48 which encodes a polypeptide fragment which has transcriptional activation activity, wherein the low stringency conditions are defined by prehybridization and hybridization at 42°C in 5X SSPE, 0.3% SDS, 200 micro

g/ml sheared and denatured salmon sperm DNA, and 25% formamide, and wash conditions are defined at 50°C for 30 minutes in 2X SSC, 0.2% SDS;

- 5 (b) a polypeptide having an amino acid sequence which has at least 50% identity with the amino acid sequence of SEQ ID NO:2 or SEQ ID NO: 49;
- (c) an allelic variant of (a) or (b);
- (d) a fragment of (a), (b), or (c), wherein the fragment has transcriptional activation activity; and
- 10 (e) a polypeptide comprising the amino acid sequence of SEQ ID NO:3, or an allelic variant thereof.
21. The polypeptide of claim 20, comprising an amino acid sequence which has at least 50%, preferably at least 60%, preferably at least 70%, more preferably at least 80%, even more preferably at least 90%, more preferably at least 95%, even more preferred 97%, and most preferred 99% identity with the amino acid sequence of SEQ ID NO:2 or SEQ ID NO: 49.
- 20
22. The polypeptide of claim 20 or 21, comprising the amino acid sequence of SEQ ID NO:2 or SEQ ID NO: 49, or a fragment thereof, wherein the fragment retains transcriptional activation activity.
- 25
23. The polypeptide of any of claims 20 to 22 which is encoded in the nucleic acid sequence contained in plasmid PEES which is contained in *Escherichia coli* DSM 12294 or the DNA sequence shown in SEQ ID NO: 48.
- 30
24. The polypeptide of any of claims 20 to 23 which comprises the amino acid sequence of SEQ ID NO:3.

25. A method for producing the polypeptide of any of claims 20 to 24 comprising (a) cultivating the host cell of claim 19 under conditions conducive for production of the polypeptide; and (b) recovering the polypeptide.

5

26. A fungal host cell useful for the production of a polypeptide, wherein the cell:

- a) is a mutant of a parent fungal cell in which the parent cell comprises one or more DNA sequences encoding a protease, the transcription of which is activated by a transcriptional activator encoded by a nucleic acid sequence of any of claims 1 to 16; and
- b) produces less of the transcriptional activator and the protease(s) than the parent cell when cultured under the same conditions.

10
15
20
27. The host cell of claim 26, wherein the reduced production of the transcriptional activator is obtained by modification or inactivation of a nucleic acid sequence present in the cell and necessary for expression of the transcriptional activator.

25
28. The host cell of claim 26 or 27, wherein the reduced production of the transcriptional activator is obtained by modification or inactivation of a control sequence required for the expression of the polypeptide.

30
29. The host cell of claim 28, wherein the control sequence is a promoter sequence, or a functional part thereof.

30
30. The host cell of any of claims 26 to 29, wherein the nucleic acid sequence to be modified or inactivated is the sequence defined in any of claims 1 to 16.

31. The host cell of any of claims 26 to 30, wherein the modification or inactivation is performed by specific or random mutagenesis, site-directed mutagenesis, PCR generated mutagenesis, nucleotide insertion and/or substitution, gene interruption or gene replacement techniques, anti-sense techniques, or a combination thereof.
5
32. A fungal host cell useful for the production of a polypeptide, wherein the host cell is a mutant of a parent cell, in which the mutant:
10
 - a) produces more of a transcriptional activator encoded by a nucleic acid sequence of any of claims 1 to 16 than the parent cell when cultured under the same conditions, and
 - b) comprises a DNA sequence encoding the polypeptide, the
15 transcription of which is activated by the transcriptional activator.
33. The host cell of claim 32, wherein the host cell produces more of the transcriptional activator than the parent cell by introducing into the parent cell one or more copies of: (i) a nucleic acid sequence of any of claims 1 to 16, (ii) the nucleic acid construct of claim 17, or (iii) the expression vector of claim 18, whereby the host cell produces more of the polypeptide than the parent cell when
20 cultured under the same conditions.
25
34. The host cell of claim 32 or 33, wherein the nucleic acid sequence encoding the transcriptional activator is operably linked to a promoter, which is stronger than the corresponding promoter of the parent cell.
30
35. The host cell of claim 34, wherein the promoter mediates the expression of a gene encoding an extracellular protease, preferably *Aspergillus oryzae* alkaline protease, *A. oryzae*

neutral metalloprotease, *A. niger* aspergillopepsin protease, *Fusarium oxysporum* trypsin-like protease or *F. venenatum* trypsin.

5 36. A fungal host cell useful for the production of a polypeptide, wherein the cell is a mutant of a parent cell in which the mutant comprises:

- a) a modification or inactivation of a transcriptional activator which is encoded in a native nucleic acid sequence of any of claims 1 to 16, or a regulatory sequence thereof, and
- b) (i) an inducible promoter operably linked to a nucleic acid sequence of any of claims 1 to 16, and (ii) a promoter sequence to which a transcriptional activator encoded by the nucleic acid sequence of any of claims 1 to 16 can bind, operably linked to a nucleic acid sequence encoding the polypeptide, wherein (i) and (ii) can be introduced simultaneously or sequentially.

20 37. The host cell of claim 36 wherein the native nucleic acid sequence, or a regulatory sequence thereof, is modified or inactivated by specific or random mutagenesis, site-directed mutagenesis, PCR generated mutagenesis, nucleotide insertion and/or substitution, gene interruption or gene replacement techniques, anti-sense techniques, or a combination thereof.

38. The host cell of claim 36 or 37, wherein the inducible promoter is selected from the group in which the induction is mediated by a carbon or nitrogen catabolite.

30

39. The host cell of any of claims 33 to 38, which further comprises a promoter sequence, wherein the promoter sequence can be activated by the transcriptional activator and is

operably linked to the nucleic acid sequence encoding the polypeptide.

40. The host cell of any of claims 33 to 39, wherein the 5 promoter sequence, or a functional part thereof, is from a protease gene.

41. The host cell of any of claims 33 to 40, wherein the 10 protease gene is *Fusarium oxysporum* trypsin-like protease gene, *Aspergillus oryzae* alkaline protease gene, *Aspergillus niger* *pacA* gene, *Aspergillus oryzae* alkaline protease gene, *A. oryzae* neutral metalloprotease gene, *A. niger* aspergillopepsin protease gene, or *F. venenatum* trypsin gene.

15

42. The host cell of any of claims 26 to 41, wherein the host cell comprises at least one copy of a nucleic acid sequence encoding the polypeptide.

20 43. The host cell of any of claims 26 to 42, wherein the host cell produces less of a native protease or a combination of native proteases than the parent cell when cultured under identical conditions.

25 44. The host cell of any of claims 26 to 43, wherein the activity of the protease is assayed by the degradation of ³H-labelled sperm whale myoglobin at pH 4.

45. A method of producing a polypeptide, comprising:
30 (a) cultivating the host cell of any of claims 26 to 44, wherein the host cell harbours a gene encoding the polypeptide, in a nutrient medium suitable for production of the polypeptide; and

(b) recovering the polypeptide from the nutrient medium of the mutant cell.

46. The method of claim 45, wherein the polypeptide is native
5 to the parent cell.

47. The method of claim 45, wherein the polypeptide is heterologous to the parent cell.

10 48. The method of claim 45, wherein the polypeptide is an antibody or portions thereof, an antigen, a clotting factor, an enzyme, a hormone or a hormone variant, a receptor or portions thereof, a regulatory protein, a structural protein, a reporter, or a transport protein.

15

49. The method of claim 48, wherein the enzyme is an oxidoreductase, transferase, hydrolase, lyase, isomerase, or ligase.

20 50. The method of claim 49, wherein the enzyme is an aminopeptidase, amylase, carbohydrase, carboxypeptidase, catalase, cellulase, chitinase, cutinase, deoxyribonuclease, dextranase, esterase, alpha-galactosidase, beta-galactosidase, glucoamylase, alpha-glucosidase, beta-glucosidase, haloperoxidase, invertase, laccase, lipase, 25 mannosidase, mutanase, oxidase, pectinolytic enzyme, peroxidase, phytase, polyphenoloxidase, proteolytic enzyme, ribonuclease, transglutaminase, or xylanase.

1/8





Fig. 1

2 / 8

**Fig. 2**

3 / 8




Fig. 3

4/8




Fig. 4

5/8




Fig. 5

6/8

ICA217 ATGACCGCTT GTCATACCTG CCGCAAGCTT AAAACTCGGT
ICA218 ATGACTGCTT GCCACACCTG CCGCAAGCTT AAAACTCGGT

ICA217 GCGATCTTGA TCCACGAGGG CATGCCTGCC GCCGCTGCCT (SEQ ID NO: 53)
ICA218 GCGATCTTGA TCCACGAGGG CATGCCTGCC GCCGCTGCCT (SEQ ID NO: 54)

Fig. 6

7/8




Fig. 7

8/8




Fig. 8

SEQUENCE LISTING

<110> Novo Nordisk A/S
<120>
5 <130>

<160> 54
10 <170> PatentIn Ver. 2.1

<210> 1
<211> 4098
<212> DNA
15 <213> E. coli DSM 12294

<220>
<221> exon
<222> (977) .. (1204)
20
<220>
<221> exon
<222> (1317) .. (1718)

25 <220>
<221> exon
<222> (1777) .. (2202)

<220>
30 <221> exon
<222> (2253) .. (3116)

<220>
<221> exon
35 <222> (3170) .. (3247)

<400> 1
ttggtgctgg aaagccatt taagggatct tataaggtaa ttgccaatgt tcagtgcgcct 60
40 atggtctttg tcgagagaaa ctctttctcg ttaagatcta catgatcgct tttgattttc 120
tctgggttca cgccgtactt tctccccgtc aatccccaac cgctgttgc cctgaccatc 180
aatgtggaac ggataagggg acaagagaaa ttgaaggagc gatcataaaa agctaatttt 240
45 ggtttattat tttttttct tataaaactc aaaaaagaaa acgaaaacga aaaaggaaaa 300
aagaaaaggt aaaaatggaaa aagaaaggcg gtcatcactt ccaataacca tcagccaaag 360
50 atacagacga gttactgacc ttcttatcct ggacttccgc ccgatccata tcttcatgat 420
aagcagggaa ccgaacaaat caacgccaac ttcagcggca gttcctcact aatttcccac 480
ttcccccccg cgcatatggt gtcccaaccc cctccctgga agcagcggga ttttagttacg 540
55 atccggttta catcgagac tcggaaaata ccatagcgca tgccaatcaa aaccctccc 600
agggtgactg gccagtatca cgaccattg tttctatctt tctagaagac ctgcagggac 660
60 atggattggc tggccgcccgt gctgccgtcc attagcgtct accccaggtc aagaacggac 720

tggacggacc cataaccaat ctaaccaaag ccaattcgt caattcccag ctggcgagca 780
5 caatccatt cccagggttg gccgccaact gtaaaaggc actatgtgtc tctccacctg 840
cccccccccc tcgatggcct ggcgtata actattctac tgcttttgc ctcttacttg 900
cctcattatt agtattttac tctactctcc agattgcctg ccagcaattg gtccaaagtg 960
10 gactttgttt gatgac atg act cga acc gtg gac gag atc aaa tac gaa acg 1012
cct tct tca tgg gag cac aag agc ttg gac gtt gcc gag gat ggc agg 1060
15 cga cta gct ccc cat tcc gac act gct cgt ccg aaa ggc cgc ata cga 1108
cga tcg atg act gcc tgt cac aca tgt cgg aag ctt aaa act aga tgt 1156
gat cta gat ccg cgc ggt cat gcg tgc cgt cgc tgt cta tct cta agg 1204
20 tcagaggcac tacctacctg ccagttgaag ctttgtcctt ctgaacgcga catgatacta 1264
gtcgtgaaat ataactgtcc caactttgct gacagtccac aatatcttta ga atc gat 1322
25 tgt aag ctg cct gaa acg acc gac cgc ttc caa gac agt gct gcg atg 1370
tgg cca gac gcc acc tcg gca att ccc tcc atc gag gag cgc ctc acc 1418
tcc cta gaa aga tgc atg agg gag atg acg ggc atg atg cga cag atg 1466
30 cta gat cac tcc cca ggt ttc gca aat gcc tcg gtt ccg cat ttg acc 1514
aaa agc atc atc acg gat gaa acc gcc tcg atg gag gga agc ccg tcg 1562
35 tcc ccc ttc ctg cct aag ccc gtt cgc ctc att cag gac ctc cag tcc 1610
gac ttc ttc gga gaa gca gag act tcc ccc gtt gac tcc cct ctc tcc 1658
agc gat ggt aac gcc aag ggc gct atc gac tct aag cta tcc ctc aaa 1706
40 ttg ttg caa acg tatgggtata cctgattgac aattacaaaa aagctgctaa 1758
tccttggcgc aaatcagg ttt gtc gat cac ttt ggc gct tgc gtt tcc att 1809
45 tac aat ctc tcc gac atc cac aac gac atg aaa gcc ccc gac tct tta 1857
ctg tat aat act gca tgc ctt cta gct tca cgc tat gta ccg ggg ata 1905
ccg aca tct acc gtg cat gct ata tac ctt caa gtg cga cat gca gta 1953
50 gtc aat att ttg tgg gaa aaa cca ccc ctg aag tat gag acc ctc caa 2001
gca ctt gca ctt ctc tgt ctc tgg cca gca acc gcc cag aaa gag cca 2049
55 ccc atg gac agc tgg ctg ctg agt ggt atc tca att aac cat gca att 2097
atc gcg ctc gat ttc cta aac tat gcg ccc tcg gaa gtc atg gtg gac 2145
aat gaa acg gct gcg cag ctg cgg cta tgg aat aca tat tgc ttg aca 2193
60 cag cta cag tgggtttcat ctaagatctc ccgtccagaa gatagctaac 2242

	aagcttagt ttt gcg gtc ggg aat gcg cgt cct ttc cat atc cag caa	2291
	aga tac ctt gac cac tgc cca cgg ata ctg gag cac cca gca gca act	2339
5	ctg gag gac gca agg gtt gta gca gaa ata cag ttg tat ttg atg aca	2387
	ttg cgg ctc cag agc aat agc agt cga atg cgg ttg gcg gac ctt gac	2435
10	tat gag gaa ata gag cga tgg aag agg gag tgg gct cac ctt ttc tgt	2483
	aag aag cct gtt ctt gtt tcc cgg gga cta cca ctg acg aga gca aca	2531
	gct ggg gaa agt tcc aca ttg gag ctg agc ctt tgg ttc tgc cag aca	2579
15	ctc ctt cac cgc aca gca atg agg ctt cag ccc aga tcc gac agg ctc	2627
	gca tct gag gtt ctg caa acc tca cgt ctg ata ata tcg cgg ttc ctc	2675
20	cag atc cgg tac tct acc gca tta agc ctt gtc gac caa gtc tat ttc	2723
	att gtc ggc tac gct gca ctg aat ctg tgc gat ttc aat ctt atg gac	2771
	ccg ctt atc gag caa gtg cag atg ttc ctg ctg cat ctc tcc ccg aac	2819
25	gaa gac cac atc gcc tac cgg ttt tcg tgc atg gtc gcc gag ttc aag	2867
	cgg cga tgt ggc agt gcg gaa tgc aat gac cca tca tcc act gtc aag	2915
30	ggg tct ccg tta tca tcc tac ggc gac agt cgt aag atg agc atg ggg	2963
	caa gca ccg ttc atg cca ccg ctc atg gat ggc atg atc gag ggg tac	3011
	ggc ttc gag caa ctg atg cca gaa gtc atg ccg agt tcc ttt ccg gat	3059
35	ggg ata ctc aac gga atg cct gtg act ggg cta gca gcg tat cgg tca	3107
	gcg acg ctg taagtaatcg agatcggtt ggaaaggaca tgagtgggg	3156
40	tggtgtgggt agt agc agt aac acc agg gat gat aac ctg cag cgg tgg	3205
	ttt agt tcc tgc cca tgg gct gaa cta aaa ccc cga acc tag	3247
	catgatgacg tgcaacgaaa ggatcataac caaggccaag taaatactaa aataaaataa	3307
45	tataattcca cacgatccac taccaccacc accaccggat ccatcagggt gccttcctgc	3367
	acaggcctat ttagtttagag ggcccgtgcc acgaaacatc acgtaattga gcgcgtttgc	3427
	ttccttgcaa cttaaacaac cccatagaca ctctcacatt cacatgccaa actactaact	3487
50	cctactgacc accagctgca ggaagccagc cagccaccat ttctaatcg gatatatctc	3547
	cgaaacgtac gctttcctcc tttgttcgga ccgttccgtg cctccgcgga gagttgaacg	3607
55	agtcagaaca cattcttttc gtttctatcg tttctttcc aaggcagcag agagacgaac	3667
	aagtcaagtgc ttgctaacta acttaccct cagcattta gtaaaactact atttaggaaa	3727
	gagtaatcat tcatcgaaga caagatgtt atttctccga tcgaccaaac aaaaacgttc	3787
60	aggtagacta agtagtagta gtatgtatgc tttgacccct ttactccact atccgttgac	3847

tgcacatagt agtaagtaac tatctaaccga gttgccgagg agagggaaagt gagtgggtgg 3907
 gagccggagg atgcccggcga gaattattaa gtcgatcatt gctagtttagt tatctttca 3967
 5 tgatgaggag aggaaggaga ggggggacgg gattagagaa ataaaactttt ctctccaatt 4027
 aattatctgg attaattaaa acttggagag gagggtaggg gagttgggta ttggtatgtt 4087
 10 gctgtgaatg t 4098

15 <210> 2
 <211> 666
 <212> PRT
 <213> E.coli DSM 12294

20 <220>
 <223> Description of Artificial Sequence: MBL1213

<400> 2
 Met Thr Arg Thr Val Asp Glu Ile Lys Tyr Glu Thr Pro Ser Ser Trp
 1 5 10 15

25 Glu His Lys Ser Leu Asp Val Ala Glu Asp Gly Arg Arg Leu Ala Pro
 20 25 30

30 His Ser Asp Thr Ala Arg Pro Lys Gly Arg Ile Arg Arg Ser Met Thr
 35 40 45

Ala Cys His Thr Cys Arg Lys Leu Lys Thr Arg Cys Asp Leu Asp Pro
 50 55 60

35 Arg Gly His Ala Cys Arg Arg Cys Leu Ser Leu Arg Ile Asp Cys Lys
 65 70 75 80

40 Leu Pro Glu Thr Thr Asp Arg Phe Gln Asp Ser Ala Ala Met Trp Pro
 85 90 95

45 Asp Ala Thr Ser Ala Ile Pro Ser Ile Glu Glu Arg Leu Thr Ser Leu
 100 105 110

Glu Arg Cys Met Arg Glu Met Thr Gly Met Met Arg Gln Met Leu Asp
 45 115 120 125

His Ser Pro Gly Phe Ala Asn Ala Ser Val Pro His Leu Thr Lys Ser
 130 135 140

50 Ile Ile Thr Asp Glu Thr Ala Ser Met Glu Gly Ser Pro Ser Ser Pro
 145 150 155 160

Phe Leu Pro Lys Pro Val Arg Leu Ile Gln Asp Leu Gln Ser Asp Phe
 55 165 170 175

Phe Gly Glu Ala Glu Thr Ser Pro Val Asp Ser Pro Leu Ser Ser Asp
 180 185 190

60 Gly Asn Ala Lys Gly Ala Ile Asp Ser Lys Leu Ser Leu Lys Leu Leu
 195 200 205

Gln Thr Phe Val Asp His Phe Gly Ala Cys Val Ser Ile Tyr Asn Leu
 210 215 220

Ser Asp Ile His Asn Asp Met Lys Ala Pro Asp Ser Leu Leu Tyr Asn
 5 225 230 235 240

Thr Ala Cys Leu Leu Ala Ser Arg Tyr Val Pro Gly Ile Pro Thr Ser
 245 250 255

10 Thr Val His Ala Ile Tyr Leu Gln Val Arg His Ala Val Val Asn Ile
 260 265 270

Leu Trp Glu Lys Pro Pro Leu Lys Tyr Glu Thr Leu Gln Ala Leu Ala
 15 275 280 285

Leu Leu Cys Leu Trp Pro Ala Thr Ala Gln Lys Glu Pro Pro Met Asp
 290 295 300

Ser Trp Leu Leu Ser Gly Ile Ser Ile Asn His Ala Ile Ile Ala Leu
 20 305 310 315 320

Asp Phe Leu Asn Tyr Ala Pro Ser Glu Val Met Val Asp Asn Glu Thr
 325 330 335

25 Ala Ala Gln Leu Arg Leu Trp Asn Thr Tyr Cys Leu Thr Gln Leu His
 340 345 350

Phe Ala Val Gly Asn Ala Arg Pro Phe His Ile Gln Gln Arg Tyr Leu
 30 355 360 365

Asp His Cys Pro Arg Ile Leu Glu His Pro Ala Ala Thr Leu Glu Asp
 370 375 380

Ala Arg Val Val Ala Glu Ile Gln Leu Tyr Leu Met Thr Leu Arg Leu
 35 385 390 395 400

Gln Ser Asn Ser Ser Arg Met Arg Leu Ala Asp Leu Asp Tyr Glu Glu
 405 410 415

40 Ile Glu Arg Trp Lys Arg Glu Trp Ala His Leu Phe Cys Lys Lys Pro
 420 425 430

Val Leu Val Ser Arg Gly Leu Pro Leu Thr Arg Ala Thr Ala Gly Glu
 45 435 440 445

Ser Ser Thr Leu Glu Leu Ser Leu Trp Phe Cys Gln Thr Leu Leu His
 450 455 460

Arg Thr Ala Met Arg Leu Gln Pro Arg Ser Asp Arg Leu Ala Ser Glu
 50 465 470 475 480

Val Leu Gln Thr Ser Arg Leu Ile Ile Ser Arg Phe Leu Gln Ile Arg
 485 490 495

55 Tyr Ser Thr Ala Leu Ser Leu Val Asp Gln Val Tyr Phe Ile Val Gly
 500 505 510

Tyr Ala Ala Leu Asn Leu Cys Asp Phe Asn Leu Met Asp Pro Leu Ile
 60 515 520 525

Glu Gln Val Gln Met Phe Leu Leu His Leu Ser Pro Asn Glu Asp His

	530	535	540
	Ile Ala Tyr Arg Phe Ser Cys Met Val Ala Glu Phe Lys Arg Arg Cys		
5	545	550	555
	Gly Ser Ala Glu Cys Asn Asp Pro Ser Ser Thr Val Lys Gly Ser Pro		
	565	570	575
10	Leu Ser Ser Tyr Gly Asp Ser Arg Lys Met Ser Met Gly Gln Ala Pro		
	580	585	590
	Phe Met Pro Pro Leu Met Asp Gly Met Ile Glu Gly Tyr Gly Phe Glu		
	595	600	605
15	Gln Leu Met Pro Glu Val Met Pro Ser Ser Phe Pro Asp Gly Ile Leu		
	610	615	620
	Asn Gly Met Pro Val Thr Gly Leu Ala Ala Tyr Arg Ser Ala Thr Leu		
20	625	630	635
	Ser Ser Asn Thr Arg Asp Asp Asn Leu Gln Arg Trp Phe Ser Ser Cys		
	645	650	655
25	Pro Trp Ala Glu Leu Lys Pro Arg Thr Pro		
	660	665	

30	<210> 3 <211> 35 <212> PRT <213> Aspergillus niger		
35	<220> <223> Description of Artificial Sequence: PepApr		
40	<400> 3 Met Thr Ala Cys His Thr Cys Arg Lys Leu Lys Thr Arg Cys Asp Leu 1 5 10 15		
	Asp Pro Arg Gly His Ala Cys Arg Arg Cys Leu Ser Leu Arg Ile Asp 20 25 30		
45	Cys Lys Leu 35		

50	<210> 4 <211> 2542 <212> DNA <213> Artificial Sequence		
55	<220> <223> Description of Artificial Sequence: PCR Fragment prt13 allele		
60	<400> 4 gacatggatt ggctggccgc cgtgctgccc tccattagcg tctaccagg gtcaagaacg 60 gactggacgg acccataacc aatctaacca aagccaattt cgtcaattcc cagctggcga 120 gcacaatccc attccccagg ttggccgcca actgttaaaa ggcactatgt gtctctccac 180		

ctgcccggcc ccctcgatgg cctgcgcgt aataactatt tactgcttt tgccctttac 240
 ttgcctcatt attagtatt tactctactc tccagattgc ctgccagcaa ttgtccaaa 300
 gtggactttg tttgatgaca tgactcgaac cgtggacgag atcaaatacg aaacgccttc 360
 ttcatggag cacaagagct tggacggtgc cgaggatggc aggcgactag ctccccattc 420
 5 cgacactgct cgtccgaaag gcccgcatacg acgatcgatg actgcctgtc acacatgtcg 480
 gaagcttaaa actagatgtg atctagatcc ggcgcgtcat ggcgcgtc gctgtctatc 540
 tctaaggta gaggcactac ctacctgcca gttgaagctt tgccttctg aacgcgacat 600
 gatactagtc gtgaaatata actgtcccaa cttgctgac agtccacaat atcttttagaa 660
 tcgattgtaa gtcgcctgaa acgaccgacc gcttccaaga cagtgctgcg atgtggccag 720
 10 acgcccaccc gggcatatccc tccatcgagg agccgcctcac ctcccttagaa agatgcata 780
 gggagatgac gggcatgtatc cgacagatgc tagatcactc cccaggttgc gcaaatgcct 840
 cggttccgca ttgacccaaa agcatcatca cgatgaaac cgccctogatg gagggaaagcc 900
 cgtcgcccc cttccctgcct aagcccggtc gcctcattca ggacctccag tccgacttct 960
 tcggagaagc agagacttc cccgttact cccctctctc cagcgatgtt aacgccaagg 1020
 15 ggcgtatcga ctctaagcta tccctcaaat tggcaaac gatatggat acctgattga 1080
 caattaccaa aaagctgcta atccttggcg caaatcagggt ttgtcgatca ctttggcgct 1140
 tgcgttccca ttatcattct ctccgcatac cacaacgaca taaaagcccc cgactctta 1200
 ctgtataata ctgcgtgcct tctagttca cgctatgtac cggggatacc gacatctacc 1260
 gtgcgtgcata tatacctca agtgcgacat gcagtagtca atatttgtg ggaaaaacca 1320
 20 cccctgaagt atgagaccct ccaagactt gcacttctct gtctctggcc agcaaccgccc 1380
 cagaagagc caccatggc cagctggctg ctgagtgta ttcattaa ccatgcaatt 1440
 atcgcgtcg atttcctaaa ctatgcgtcc tcggaaatca tggggacaa taaaacggct 1500
 ggcgcgtgc ggctatggaa tacatattgc ttgacacagc tacagtgggt ttcatctaag 1560
 atctccgtc cagaagatag ctaacaagct ttatgttgc ggccggaaat ggcgtccct 1620
 25 tccatatcca gcaaagatac ttgaccact gccacccggat actggagcac ccaggcagcaa 1680
 ctctggagga cgcaagggtt gtagcagaaa tacagttgtt tttgatgaca ttgcggctcc 1740
 agagcaatag cagtcgaatg cgggtggcg accttgacta tgaggaaata gaggatggaa 1800
 agagggagtg ggctcacctt ttctgttcaaga agcctgttct tggggccgg ggactaccac 1860
 tgacgagagc aacagctgg gaaagttcca cattggagct gagcctttgg ttctgcccaga 1920
 30 cactcctca cccgcacagca atgaggcttc agcccgatc cgacaggctc gcatctgagg 1980
 ttctgcaaac ctcacgtctg ataataatcgc gttccttca gatccggatc tctaccgc 2040
 taagccttgt cgaccaagtc tatttcatttgc tccgtacgc tgcactgaat ctgtgcgatt 2100
 tcaatcttat ggacccgctt atcgagcaag tgcagatgtt cctgtgtcat ctctccccga 2160
 acgaagacca catcgcttac cgggtttcgat gcatggtcg cggatgttcaag cggcgatgtg 2220
 35 gcaatgcggaa atgcaatgac ccatcatcca ctgtcaaggg gttccgtta tcatcctacg 2280
 ggcgcgtcg taatgtgac atggggcaag caccgttcat gccaccgc atggatggca 2340
 tgatcgaggg gtacggcttc gagcaatgaa tggcagaatg catggcgatg tcccttccgg 2400
 atgggataact caacggaaatg cctgtgactg ggcttagcgc gtatcggtca ggcacgctgt 2460
 aagtaatcga gatcggttg gaaaggacat gatgggggtt ggtgggtt gtagcgtaa 2520
 40 caccaggat gataaccctgc ag 2542

<210> 5
 <211> 665
 45 <212> PRT
 <213> Aspergillus niger

<400> 5
 Met Thr Arg Thr Val Asp Glu Ile Lys Tyr Glu Thr Pro Ser Ser Trp
 50 1 5 10 15

Glu	His	Lys	Ser	Leu	Asp	Val	Ala	Glu	Asp	Gly	Arg	Arg	Ley	Ala	Pro
20															

55 His Ser Asp Thr Ala Arg Pro Lys Gly Arg Ile Arg Arg Ser Met Thr
 35 40 45

Ala	Cys	His	Thr	Cys	Arg	Lys	Leu	Lys	Thr	Arg	Cys	Asp	Leu	Asp	Pro
50															

60 Arg Gly His Ala Cys Arg Arg Cys Leu Ser Ley Arg Ile Asp Cys Lys

	65	70	75	80
	Leu Pro Glu Thr Thr Asp Arg Phe Gln Asp Ser Ala Ala Met Trp Pro			
	85		90	95
5	Asp Ala Thr Ser Ala Ile Pro Ser Ile Glu Glu Arg Leu Thr Ser Pro			
	100	105		110
	Glu Arg Cys Met Arg Glu Met Thr Gly Met Met Arg Gln Met Leu Asp			
10	115	120		125
	His Ser Pro Gly Phe Ala Asn Ala Ser Val Pro His Leu Thr Lys Ser			
	130	135	140	
15	Ile Ile Thr Asp Glu Thr Ala Ser Met Glu Gly Ser Pro Ser Ser Pro			
	145	150	155	160
	Phe Leu Pro Lys Pro Val Arg Leu Ile Gln Asp Leu Gln Ser Asp Phe			
	165	170		175
20	Phe Gly Glu Ala Glu Thr Ser Pro Val Asp Ser Pro Leu Ser Ser Asp			
	180	185	190	
	Gly Asn Ala Lys Gly Ala Ile Asp Ser Lys Leu Ser Leu Lys Leu Leu			
25	195	200	205	
	Gln Thr Phe Val Asp His Phe Gly Ala Cys Val Ser Ile Tyr Asn Leu			
	210	215	220	
30	Ser Asp Ile His Asn Asp Met Lys Ala Pro Asp Ser Leu Leu Tyr Asn			
	225	230	235	240
	Thr Ala Cys Leu Leu Ala Ser Arg Tyr Val Pro Gly Ile Pro Thr Ser			
	245	250	255	
35	Thr Val His Ala Ile Tyr Leu Gln Val Arg His Ala Val Val Asn Ile			
	260	265	270	
	Leu Trp Glu Lys Pro Pro Leu Lys Tyr Glu Thr Leu Gln Ala Leu Ala			
40	275	280	285	
	Leu Leu Cys Leu Trp Pro Ala Thr Ala Gln Lys Glu Pro Pro Met Asp			
	290	295	300	
45	Ser Trp Leu Leu Ser Gly Ile Ser Ile Asn His Ala Ile Ile Ala Leu			
	305	310	315	320
	Asp Phe Leu Asn Tyr Ala Pro Ser Glu Val Met Val Asp Asn Glu Thr			
	325	330	335	
50	Ala Ala Gln Leu Arg Leu Trp Asn Thr Tyr Cys Leu Thr Gln Leu His			
	340	345	350	
	Phe Ala Val Gly Asn Ala Arg Pro Phe His Ile Gln Gln Arg Tyr Leu			
55	355	360	365	
	Asp His Cys Pro Arg Ile Leu Glu His Pro Ala Ala Thr Leu Glu Asp			
	370	375	380	
60	Ala Arg Val Val Ala Glu Ile Gln Leu Tyr Leu Met Thr Leu Arg Leu			
	385	390	395	400

Gln Ser Asn Ser Ser Arg Met Arg Leu Ala Asp Leu Asp Tyr Glu Glu
405 410 415

5 Ile Glu Arg Trp Lys Arg Glu Trp Ala His Leu Phe Cys Lys Lys Pro
420 425 430

Val Leu Val Ser Arg Gly Leu Pro Leu Thr Arg Ala Thr Ala Gly Glu
435 440 445

10 Ser Ser Thr Leu Glu Leu Ser Leu Trp Phe Cys Gln Thr Leu Leu His
450 455 460

Arg Thr Ala Met Arg Leu Gln Pro Arg Ser Asp Arg Leu Ala Ser Glu
15 465 470 475 480

Val Leu Gln Thr Ser Arg Leu Ile Ile Ser Arg Phe Leu Gln Ile Arg
485 490 495

20 Tyr Ser Thr Ala Leu Ser Leu Val Asp Gln Val Tyr Phe Ile Val Gly
500 505 510

Tyr Ala Ala Leu Asn Leu Cys Asp Phe Asn Leu Met Asp Pro Leu Ile
515 520 525

25 Glu Gln Val Gln Met Phe Leu Leu His Leu Ser Pro Asn Glu Asp His
530 535 540

Ile Ala Tyr Arg Phe Ser Cys Met Val Ala Glu Phe Lys Arg Arg Cys
30 545 550 555 560

Gly Ser Ala Glu Cys Asn Asp Pro Ser Ser Thr Val Lys Gly Ser Pro
565 570 575

35 Leu Ser Ser Tyr Gly Asp Ser Arg Lys Met Ser Met Gly Gln Ala Pro
580 585 590

Phe Met Pro Pro Leu Met Asp Gly Met Ile Glu Gly Tyr Gly Phe Glu
595 600 605

40 Gln Leu Met Pro Glu Val Met Pro Ser Ser Phe Pro Asp Gly Ile Leu
610 615 620

Asn Gly Met Pro Val Thr Gly Leu Ala Ala Tyr Arg Ser Ala Thr Leu
45 625 630 635 640

Ser Ser Asn Thr Arg Asp Asp Asn Leu Gln Arg Trp Phe Ser Ser Cys
645 650 655

50 Pro Trp Ala Glu Leu Lys Pro Arg Thr
660 665

55 <210> 6
<211> 29
<212> DNA
<213> Artificial Sequence

60 <220>
<223> Description of Artificial Sequence: PepApr

5 <400> 6
10 cgaaattcgc atgctggagg tgcttctaa 29

10 5 <210> 7
15 <211> 33
20 <212> DNA
25 <213> Artificial Sequence
30 10 <220>
35 <223> Description of Artificial Sequence: PepA/amdS
40 15 <400> 7
45 ttcccaggat tgaggcattt tgaccacgag att 33

50 20 <210> 8
55 <211> 17
60 <212> DNA
65 <213> Artificial Sequence
70 25 <220>
75 <223> Description of Artificial Sequence: MBL1213
80 30 <400> 8
85 taacttccac cgaggtc 17

90 35 <210> 9
95 <211> 18
100 <212> DNA
105 <213> Artificial Sequence
110 40 <220>
115 <223> Description of Artificial Sequence: Primer 122958
120 45 <400> 9
125 cgatcgatga ctgcctgt 18

130 50 40 <210> 10
135 <211> 18
140 <212> DNA
145 <213> Artificial Sequence
150 55 <220>
155 <223> Description of Artificial Sequence: Primer 122956
160 50 50 <400> 10
165 agagacacat agtgcctt 18

170 55 55 <210> 11
175 <211> 18
180 <212> DNA
185 <213> Artificial Sequence
190 60 55 <220>
195 <223> Description of Artificial Sequence: Primer 122959

<400> 11
gcttatagtc gatagcgc 18

5 <210> 12
<211> 18
<212> DNA
<213> Artificial Sequence

10 <220>
<223> Description of Artificial Sequence: Primer 122960

<400> 12
cctctctcca gcgatgg 18

15 <210> 13
<211> 18
<212> DNA
20 <213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Primer122962

25 <400> 13
atggaataca tactgctt 18

<210> 14
30 <211> 18
<212> DNA
<213> Artificial Sequence

<220>
35 <223> Description of Artificial Sequence: Primer122961

<400> 14
atgaaaccca ctgttagct 18

40 <210> 15
<211> 18
<212> DNA
<213> Artificial Sequence

45 <220>
<223> Description of Artificial Sequence: Primer 122963

<400> 15
50 tgctcgataa gcgggtcc 18

<210> 16
<211> 18
55 <212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Primer 122964

60 <400> 16

attcttatgg acccgctt 18

5 <210> 17
 <211> 20
 <212> DNA
 <213> Artificial Sequence

10 <220>
 <223> Description of Artificial Sequence: Primer 124289

 <400> 17
 ccccgggaaa caagaacagg 20

15 <210> 18
 <211> 20
 <212> DNA
 <213> Artificial Sequence

20 <220>
 <223> Description of Artificial Sequence: Primer 124290

 <400> 18
25 gttgcggac cttgactatg 20

 <210> 19
 <211> 22
30 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Primer 125112

35 <400> 19
 acagctacag tgggttcat ct 22

40 <210> 20
 <211> 19
 <212> DNA
 <213> Artificial Sequence

45 <220>
 <223> Description of Artificial Sequence: Primer 125111

 <400> 20
 agtcaacggg ggaagtctc 19

50 <210> 21
 <211> 20
 <212> DNA
55 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Primer 128330

60 <400> 21
 ctagcagcgt atcggtcagc 20

<210> 22
<211> 19
5 <212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Primer 130887
10 <400> 22
cttggaaaag aaacgatag 19

15 <210> 23
<211> 19
<212> DNA
<213> Artificial Sequence

20 <220>
<223> Description of Artificial Sequence: Primer 130888

<400> 23
aacgtacgct ttcctccct 25

25 <210> 24
<211> 21
<212> DNA
30 <213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Primer 134135

35 <400> 24
gggtccagtcc agtccggttct t 21

40 <210> 25
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
45 <223> Description of Artificial Sequence: Primer -48
reverse

<400> 25
agcggataac aatttcacac agga 50

50 <210> 26
<211> 17
<212> DNA
55 <213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Primer-40
Universal
60 <400> 26

gttttccccag tcacgac 17

5 <210> 27
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
10 <223> Description of Artificial Sequence: Primer PstI
<400> 27
tcatccctgg tgttactgc 19

15 <210> 28
<211> 17
<212> DNA
<213> Artificial Sequence

20 <220>
<223> Description of Artificial Sequence: PstII
<400> 28
25 catggattgg ctggccg 17

30 <210> 29
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
35 <223> Description of Artificial Sequence: Prt270n
<400> 29
tactctccag attgcctg 18

40 <210> 30
<211> 18
<212> DNA
<213> Artificial Sequence

45 <220>
<223> Description of Artificial Sequence: Prt1420r
<400> 30
tgagatacca ctcagcag 18

50 <210> 31
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
55 <223> Description of Artificial Sequence: Prt1350n
<400> 31
tgcacctctc tgtctctg 18

5 <210> 32
<211> 18
<212> DNA
<213> Artificial Sequence

10 <220>
<223> Description of Artificial Sequence: Prt2365r

15 <400> 32
gacttctggc atcagttg 18

20 <210> 33
<211> 18
<212> DNA
<213> Artificial Sequence

25 <220>
<223> Description of Artificial Sequence: Prt2320n

30 <400> 33
ctcatggatg gcatgatc 18

35 <210> 34
<211> 33
<212> PRT
<213> Aspergillus niger

40 <220>
<221> ZN_FING
<222> (1)..(33)

45 <400> 34
Met Thr Ala Cys His Thr Cys Arg Lys Leu Lys Thr Arg Cys Asp Leu
1 5 10 15

50 Asp Pro Arg Gly His Ala Cys Arg Arg Cys Leu Ser Leu Arg Ile Asp
20 25 30

55 Cys

60 <210> 35
<211> 20
<212> DNA
<213> Artificial Sequence

65 <220>
<223> Description of Artificial Sequence: Degenerated
Primer 137396

70 <400> 35
atgacygcgt gycayacytg 20

75 <210> 36

<211> 20
<212> DNA
<213> Artificial Sequence

5 <220>
<223> Description of Artificial Sequence: Degenerated
Primer 137397

<400> 36
10 arrcancgnc grcargcrtg 20

<210> 37
<211> 20
15 <212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Primer 137394
20

<400> 37
atgactgcct gtcacacatg 20

25 <210> 38
<211> 20
<212> DNA
<213> Artificial Sequence

30 <220>
<223> Description of Artificial Sequence: Primer 137395

<400> 38
agacagcgac ggcacgcattg 20
35

<210> 39
<211> 21
<212> DNA
40 <213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Primer 144428

45 <400> 39
caccgagttt taagcttgcg g 21

<210> 40
50 <211> 20
<212> DNA
<213> Artificial Sequence

<220>
55 <223> Description of Artificial Sequence: Primer 144429

<400> 40
gcgatcttga tccacgagg 20

60 <210> 41

<211> 21
<212> DNA
<213> Artificial Sequence

5 <220>
<223> Description of Artificial Sequence: Primer 153468

<400> 41
cgggatgaat tgttagagagg c 21

10

<210> 42
<211> 25
<212> DNA
15 <213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Primer 140358

20 <400> 42
cgcaagctta aaactcggtg cgatc 25

<210> 43
25 <211> 20
<212> DNA
<213> Artificial Sequence

<220>
30 <223> Description of Artificial Sequence: Primer 140359

<400> 43
cctcgtggat caagatcgca 20

35

<210> 44
<211> 22
<212> DNA
<213> Artificial Sequence

40 <220>
<223> Description of Artificial Sequence: Primer 175653

<400> 44
45 gatgaaaaga ataatcgacg ag 22

<210> 45
<211> 21
50 <212> DNA
<213> Artificial Sequence

<220>
55 <223> Description of Artificial Sequence: Primer 175654

<400> 45
cgccggcacac taccccccgtt g 21

60 <210> 46
<211> 22

<212> DNA
<213> Artificial Sequence

<220>

5 <223> Description of Artificial Sequence: Primer B043G08

<400> 46
atctagctca agcattagcg gc 22

10 <210> 47
<211> 21
<212> DNA
<213> Artificial Sequence

15 <220>

<223> Description of Artificial Sequence: Primer
B0403G09

20 <400> 47
aatttcggcc cttagtgc c 21

<210> 48
25 <211> 2931
<212> DNA
<213> Aspergillus oryzae

<220>

30 <221> intron
<222> (1028) .. (1135)

<220>

<221> intron
35 <222> (1538) .. (1591)

<220>

<221> intron
<222> (2018) .. (2066)

40 <220>

<221> intron
<222> (2297) .. (2347)

45 <400> 48
gatatctcat gatctgcgtg atcggottgc ctccatcttt agatcacccg ggcttcttca 60
aatcagcaac aacgctcaga catgtccccct gagaggttat ccaaattata cacagagagaa 120
cgcgaaaacg caaaattaagg atgagcgaaa aagagaaaaaa aatccgttgt tcctgagtca 180
tgacgaatga gcaaaaagtca aacacacctt ctgttttgg ggggtatgcc cgatcacaat 240
50 cttcaaccgg ccatgataag agacacacgc tatcgacaaa tcacoggagg tcaagattag 300
tggcgttcct tagctaattt cagggtggcg tcaacccctt ccaacccaaac ccaacccccc 360
catggaagcg ggactcccta tggagccggc ttacatcgaaa cgcactgcaa tggcgacgt 420
caatcaaccc ctctcttgtt gcagtgccta gtatgcacaa ccacccttc tattcttca 480
gaaaccacac ccttagagact cggatotaca cggattgggtt ggaatgtcc gattagttgg 540
55 catttacccca aggtcaaaat ggataatcaa tctaacggag tctatccgtt caactgcctg 600
ccagctagca caatctccctt ttcaccccg gccgtgggtt gttaaaagggtt tcaattccct 660
ccccacccgtt gtggattctt tatgatttgc acgggatctg acttgggttc cacaattctt 720
cttgctctca gcttggctca ctcggccgatt attctttca tcaacccggc acactacccc 780
cgttgtctga tgtcatgact agaactactg ttgaacctat caaatatgg gccccttgcgt 840
60 gggagcataa gagcgtgcattt gtgtccgacg accacaggag aatcatcccc aatgtccggcg 900
acgacgcgac gcgcccaaag ggccgcattt gacgttcaat gaccgcttgcgt aataccctgcc 960

gcaagcttaa aactcggtgc gatcttgate cacgaggcga tgcatgccgg cggtgtctat 1020
 cttaaggc ggggccacc gttatccact ttgtcaaatc tcttacgtca aaatggggga 1080
 tcccatgtcc tgccaagacc aaataagct ttcttgagta ctaatgttc tataggatcg 1140
 actgtcagct cccccagacg agtgagcgt ttcaggacag tactccaatg tggcagacg 1200
 5 caacgacago tatecccctcc atcgaggagc gtctacttc octagagagg agtatgagag 1260
 agatgaccgg catgcttcgg cagatctga atcaatcacc aagcgtctct aatatctccg 1320
 tccctccgct agctcgaggt gttcatacgg aagaaacggc ctccattgaa ggaaactcat 1380
 tcggccctt cctacctaa cccgttccgc taattcagga cctccaatct gagtttttg 1440
 gggagacaaa ccgcattccct gttgaatctc ctttcttggg taacagttt gagaaggta 1500
 10 tcttagattc taagtgtct ctcaagttgg tacagctgtc tggcactcg tcattgtccat 1560
 ctgcctctat agccgctaatt gcttgagctc gatttggta taatttccgc cctttagtgt 1620
 ccataaataa tcagtcggac ttccacaacg agatgaggaa caccgattcg ttgttatata 1680
 gtactgcctg tcttctggcc tcccgatatg tgccaggcat accaccacccg attgtccata 1740
 15 ccatgaacct ccaagttcga cataaggcag tcaatctgtc gtggaaagaa ccgccttga 1800
 aatacgaatc gtcgccaggca ctgcoccctc ttgtttatg gccagcggcg ggtcaaagg 1860
 agttccccat agatggctgg ttactgagcg ggactgcaat caatcatgcc ctgcgtctct 1920
 ttgacttccat cttctgttgc ctttcagagc ttctcattga taacgatatac gccgctcaat 1980
 tgccgtctg gaacgcttc tggtaaacac agttacagta ggtacaacat ttccggctta 2040
 actccaactt gctaattgcag aaatagtttgc ttgttggca acgcacgtcc attccattta 2100
 20 ccacagagat atctcgatata ttgcccacga ctcttgcgac accccgtgc aacagtttag 2160
 gatggcaagg tcgttagcaga gatccagtt tacttgatca cattgcgact ccaagccaa 2220
 gagcaacgta tgcgattcgc ggaggtgaa tacgaagaga ttgaacgatg gaaagttgaa 2280
 tgggcccattc ttcttggtaa ggttaagcaa cgaggaccat ctcatataaa tgctaactat 2340
 tcaacagctg gtgtatgaaaa ttcaacattt gagcttagtc tctggttctg tcaaattcctc 2400
 25 ctgcattcgga cagcaatgag gttccaaggcg gactctgaga gactcacgtc ggaaattctc 2460
 caaggatcgc gttgtatcat ctgcatttc ctgcactcc gatttgcac cgctctaaga 2520
 gtggcgtatc aggctactt catcgctgg tatgcgcgtc taaatcttg cgacttcaac 2580
 ttccctcgacc ccctcattga ccagatccag atgtttctgc tgcatctgtc gccaaacgaa 2640
 gaccacatcg cataccgggtt ttcgtgcattg atagccgagt tcaagcgtcg ctgtgcccga 2700
 30 tgcaacgacc ctgcagcgc agtcgacggc tctcaatgtc ctttcggaga tgcccggaa 2760
 atgagcatgg aacaggataca attcgtgcca ccactagtag atagcatgtat tggggatata 2820
 agcgctctgg aacagctgtat ccctgaggc atgcccacact catitccgga aagtgtcata 2880
 agtggcatgg ctgtgactga agccattccct gtggatcgcc cgccatacta g 2931

35

<210> 49
 <211> 624
 <212> PRT
 <213> Aspergillus oryzae

40

<400> 49
 Met Thr Arg Thr Thr Val Glu Pro Ile Lys Tyr Glu Ala Pro Ser Trp
 1 5 10 15

45

Glu His Lys Ser Val His Val Ser Asp Asp His Gly Arg Ile Ile Pro
 20 25 30
 Asn Val Gly Asp Asp Ala Thr Arg Pro Lys Gly Arg Ile Arg Arg Ser

50

35 40 45
 Met Thr Ala Cys Asn Thr Cys Arg Lys Leu Lys Thr Arg Cys Asp Leu
 50 55 60

55

Asp Pro Arg Gly His Ala Cys Arg Arg Cys Leu Ser Leu Arg Ile Asp
 65 70 75 80

Cys Gln Leu Pro Glu Thr Ser Glu Arg Phe Gln Asp Ser Thr Pro Met
 85 90 95

60

Trp Ser Asp Ala Thr Thr Ala Ile Pro Ser Ile Glu Glu Arg Leu Thr
 100 105 110

Ser Leu Glu Arg Ser Met Arg Glu Met Thr Gly Met Leu Arg Gln Ile
 115 120 125
 5 Leu Asn Gln Ser Pro Ser Val Ser Asn Ile Ser Val Pro Pro Leu Ala
 130 135 140
 Arg Ser Val His Thr Glu Glu Thr Ala Ser Ile Glu Gly Asn Ser Phe
 145 150 155 160
 10 Gly Pro Phe Leu Pro Lys Pro Val Arg Leu Ile Gln Asp Leu Gln Ser
 165 170 175
 Glu Phe Phe Gly Glu Thr Asn Arg Ile Pro Val Glu Ser Pro Phe Leu
 15 180 185 190
 Gly Asn Ser Phe Glu Lys Gly Ile Leu Asp Ser Lys Leu Ser Leu Lys
 195 200 205
 20 Leu Val Gln Leu Phe Val Asp Asn Phe Gly Pro Leu Val Ser Ile Asn
 210 215 220
 Asn Gln Ser Asp Phe His Asn Glu Met Arg Asn Thr Asp Ser Leu Leu
 225 230 235 240
 25 Tyr Ser Thr Ala Cys Leu Leu Ala Ser Arg Tyr Val Pro Gly Ile Pro
 245 250 255
 Pro Pro Ile Val His Thr Met Asn Leu Gln Val Arg His Lys Ala Val
 30 260 265 270
 Asn Leu Leu Trp Glu Glu Pro Pro Leu Lys Tyr Glu Ser Leu Gln Ala
 275 280 285
 35 Leu Ala Leu Leu Cys Leu Trp Pro Ala Ala Gly Gln Lys Glu Phe Pro
 290 295 300
 Ile Asp Gly Trp Leu Leu Ser Gly Thr Ala Ile Asn His Ala Leu Val
 305 310 315 320
 40 Ser Phe Asp Phe Leu Asn His Val Pro Ser Glu Leu Leu Ile Asp Asn
 325 330 335
 Asp Ile Ala Ala Gln Leu Arg Leu Trp Asn Ala Phe Cys Leu Thr Gln
 45 340 345 350
 Leu His Phe Ala Val Gly Asn Ala Arg Pro Phe His Leu Pro Gln Arg
 355 360 365
 50 Tyr Leu Asp Tyr Cys Pro Arg Leu Leu Glu His Pro Ala Ala Thr Val
 370 375 380
 Glu Asp Gly Lys Val Val Ala Glu Ile Gln Leu Tyr Leu Ile Thr Leu
 385 390 395 400
 55 Arg Leu Gln Ala Asn Glu Gln Arg Met Arg Phe Ala Glu Val Glu Tyr
 405 410 415
 Glu Glu Ile Glu Arg Trp Lys Val Glu Trp Ala His Leu Leu Ala Gly
 60 420 425 430

	aggtagcagaa	gtccaattgc	ttccgatctg	gtaaaagatt	cacgagatag	tacottctcc	720
	gaagttagta	gagcgagtac	ccggcgctgta	agctccctaa	ttggcccatc	cggoatctgt	780
	agggcggtcca	aatatcgtgc	ctctcctgct	ttgcccggtg	tatgaaaccg	gaaaggccgc	840
5	tcaggagctg	gccagcggcg	cagaccggga	acacaagctg	gcagtcgacc	catccggtgc	900
	tctgaactcg	acctgctgag	gtccctca	ccctggtagg	cagcttgc	ccgtctgtcc	960
	gcccggtgtg	tcggcggggt	tgacaaggc	gttgcgtcag	tccaacattt	gttgcata	1020
	tttcctgctc	tccccaccag	ctgtagatct	tggtgccgt	aaactccgc	accttctcg	1080
	ccagogcctt	gtagaagcgc	gtatggctc	gtacccggc	catcaacacg	cgtotgcgtt	1140
	cgaccaggct	gcbcgttctc	gcccgcata	caaccgcacgt	acggcg	tgccotcgccg	1200
10	gcagcaagaa	gcccacggaa	tccgcccga	gcagaaaatg	cccacgc	tgccgggttta	1260
	tatagacgg	ccccacggg	tggggaaaac	caccaccacg	caactgc	tggccctggg	1320
	ttcgcgcac	gatatcg	acgtacccg	gcccgtgact	tactggccgg	tgctgggggc	1380
	ttccgagaca	atcgcgaaca	tctacaccac	acaacacgc	ctcgaccagg	gtgagatata	1440
15	ggccggggac	gcccgggtg	taatgacaa	cgcccagata	acaatggca	tgccttatgc	1500
	cgtgaccgac	gcccgttctg	ctcctcata	cgggggggag	gtgggagct	cacatgcccc	1560
	gccccggccc	ctcacccctca	tcttcgacc	ccatcccatc	gcccgc	tgtgtaccc	1620
	ggccgcgcgg	taccttatgg	gcagcatgac	cccccaggcc	gtgctggcgt	tcgtggccct	1680
	catccgcgcg	accttgc	gcaccaacat	cggtcttggg	gcccctccgg	aggacagaca	1740
20	catcgaccgc	ctggccaaac	gccagcgccc	cgccgcgcgg	ctggaccctgg	ctatgcgtgc	1800
	tgcgattcgc	cgcgttac	ggctacttgc	caatacgggt	cggtatc	agtgcggccg	1860
	gtcggtggcgg	gaggactggg	gacagcttgc	ggggacggcc	gtgcgc	agggtgcga	1920
	gccccagagc	aacgcgggc	cacgacccca	tatcggggac	acgttattt	ccctgttgc	1980
	gggcgcgcgg	ttgctggccc	ccaaacggc	cctgtataac	gtgttgc	gggcgttgg	2040
25	cgtcttggcc	aaacgcctc	gttccatgc	cgtcttgc	ctggattacg	accaatgc	2100
	cgccggcgtc	cgccgcgc	tgctgcaact	tacctccggg	atggtccaga	cccacgtc	2160
	caccccgcc	tccataccg	cgatgc	cctggcgc	acgttgc	gggagatggg	2220
	ggaggcta	tgaacacgg	aaggagaca	tacccggagg	aaccgcgc	atccggatcc	2280
	acttaacgtt	actgaaatca	tcaaacacgt	tgacgatct	ggtataaga	tcgttgggt	2340
	cgatgtcagc	tccggagtt	agacaaatgg	tgttccaggat	ctcgataaga	tacgttcat	2400
30	tgtccaaagca	gcaaaagatg	ccttctatg	attaatagc	tccatgtca	caagaataaa	2460
	acgcgttttc	gggtttac	cttccagata	cagtcatct	gcaatgcatt	aatgcattga	2520
	ctgcaaccta	gtaaacgc	caggctccgg	cgaaagagaag	aatagcttgc	cagagctt	2580
	ttcattttcg	ggagacgaga	tcaagcagat	caacggcgt	caagagacct	acgagactga	2640
	ggaatccgt	cttggctcca	cgcgactata	tatttgc	taattgtact	ttgacatgt	2700
35	cctctctt	actctgatag	tttgactatg	aaaattccgt	caccagcc	gggttgc	2760
	agataattgc	atgtttcttc	tttgcactt	caaggctaca	ggacacacat	tcatcg	2820
	tataaacctc	gaatcatc	ctactaagat	ggtatacaat	agtaaccat	catgttg	2880
	tagtgaatgc	tccgtAACAC	ccaatacgcc	ggccgaaact	tttttacaac	tctccatg	2940
	gtcggttacc	cagaatgcac	aggtacactt	gtttagaggt	aatccttctt	tctagaagtc	3000
40	ctcggttact	gtgtacgc	ccactccaca	tctccactcg	acctgcaggc	atgcagat	3060
	ggcgtatca	tggtcatagc	tgttctgt	gtgaaattgt	tatccgc	caattccaca	3120
	caacatcga	ggccggagca	taaagtgtaa	agctgggggt	gcctaatgag	tgagctact	3180
	cacataatt	gcttgcgt	cactgc	tttccagtc	gaaacccgtt	cgtccagag	3240
	cgccgcctc	gcatataatg	atcgccaa	gcccggggag	aggccgttgc	cgtattggc	3300
45	gctctccgc	ttcctcgctc	actgactc	tgogctcggt	cggtcg	cgccgagccg	3360
	tatcagctca	ctcaaaggc	gtatc	tatccacaga	atcaggggat	aacgcaggaa	3420
	agaacatgt	agcaaaaggc	cagcaaaagg	ccaggaacccg	aaaaaggcc	gcgttgcgt	3480
	cgttttcca	taggctccgc	ccccctgacg	agcatcaca	aaatcgacgc	tcaagtgc	3540
	ggtggcgaaa	cccgacagga	ctataaagat	accaggcg	tccccc	ctccctcg	3600
50	tgcgtctcc	tggtccgacc	ctgccc	ccggata	gtccgc	ctccctcg	3660
	gaagcgtggc	gtttctcat	agctc	atgttatct	cagtgc	tggtcg	3720
	gctccaaagct	gggctgtgt	cacgaa	ccgttgc	cgaccgc	gccttatcc	3780
	gtaactatcg	tcttgcgtcc	aacc	gacacgactt	atcgcc	actgc	3840
	ctggtaacag	gattagcaga	gcg	aggatgt	tacagat	ttgaatgt	3900
55	ggcctaacta	cggctacact	agaaggac	tatgggtat	ctgcgtct	ctgaagccag	3960
	ttaccc	aaaaagatgt	ggtagctt	gatccggca	acaaaccacc	gctgttag	4020
	gtggttttt	tgttgc	cacgac	cgccgagaaa	aaaaggat	caagaagatc	4080
	ctttgatctt	tttacccgggg	tctgac	atgtggaa	aaactc	acgttaaggatt	4140
	tggtcatgag	attatcaaaa	aggatctca	cctagatct	tttaaaat	aaatgaagtt	4200
60	ttaaatcaat	ctaaaggata	tatgataaa	cttgc	cgttacaa	tgcttaatca	4260
	gtgaggcacc	tatctcagcg	atctgc	tatc	tgactcc	tgactcc	4320

	tctgtgttagat	aactacgata	cgggagggct	taccatctgg	ccccagtgtct	gcaatgatac	4380
	cgcgcagaccc	acgctcaccg	gctccagatt	tatcagaat	aaaccagcca	gccggaaggg	4440
	ccgagcgcag	aagtggctt	gcaactttat	ccgcctccat	ccagtctatt	aatttgtgcc	4500
	gggaagctag	agtaagttagt	tcgcccagtt	atagtttgcg	caacgttgtt	gccattgcta	4560
5	caggcatcgt	ggtgtcacgc	tcgtcggtt	gtatggcttc	attcagctcc	ggttcccaa	4620
	gatcaaggcg	agttacatga	tccccatgt	tgtcaaaaa	agcggttagc	tccttcggtc	4680
	ctccgcgtgt	tgtcagaagt	aagtggccg	cagtgttata	actcatgtt	atggcagcac	4740
	tgcataattc	tcttactgtc	atgcctatccg	taagatgtt	ttctgtgtact	ggtgagtaact	4800
10	caacccaagt	attctcgagaa	tagtgtatgc	ggcgaccggag	ttgtcttgc	ccggcgtcaa	4860
	tacgggataa	taccgcgcca	catagcgaaa	ctttaaaagt	gctcatcatt	ggaaaacgtt	4920
	cttcggggcg	aaaactctca	aggatcttac	cgtctgttag	atccagttcg	atgtaaacca	4980
	ctcggtgacc	caactgtatct	tcgcatctt	ttactttcac	cagcgtttt	gggtgagcaa	5040
	aaacaggaaag	gcaaaatgcc	gcaaaaaagg	gaataaggcc	gacacggaaa	tgttgaatac	5100
15	tcatactctt	ccttttcaa	tattattgaa	gcatttatca	gggttattgt	ctcatgagcg	5160
	gatacatatt	tgaatgtatt	tagaaaaata	aacaaatagg	ggttccgcgc	acatttcccc	5220
	gaaaagtgcc	acctgacgtc	taagaaaacca	ttattatcat	gacattaacc	tataaaaata	5280
	ggcgtatcac	gaggccctt	cgtctcgccg	gtttcggtga	tgacgggtgaa	aacctctgac	5340
	acatgcagct	cccggagacg	gtcacagctt	gtctgtaa	ggatgcccgg	agcagacaag	5400
20	cccgctcaggg	cgcgtcagcg	ggtgttggcg	ggtgtcgggg	ctggcttaac	tatgcggcat	5460
	cagagcagat	tgtactgaga	gtgcaccata	tcgacgcct	cccttatgcg	actcctgcac	5520
	taggaagcag	cccagtagta	ggttgaggcc	gttgagaoacc	gcccggccaa	ggaatggtgc	5580
	atgcaaggag	atggcggcca	acagtcccc	ggccacgggg	cctgcccacca	tacccacgca	5640
	gaaacaagcg	ctcatgagcc	cgaagtggcg	agcccgatct	tcccccattcg	tgatgtcgcc	5700
25	gatataggcg	ccgcaaccg	cacctgtggc	ggccgtgtatg	ccggccacga	tgccgtccggc	5760
	gttagaggatc	tggctagcg	tgaccctgtct	gattggttcg	ctgaccattt	ccgggggtgcg	5820
	gaacggcggtt	accagaaact	cagaaggttc	gtccaaacca	accgactctg	acggcaggtt	5880
	acgagagaga	tgatagggtc	tgcttcagta	agccagatgc	tacacaatta	ggcttgtaca	5940
	tattgtcgtt	agaacgcggc	tacaattaat	acataaccctt	atgtatcata	cacatacgt	6000
	ttaggtgaca	ctata					6015

30

<210> 51
<211> 18

<212> DNA

<220>
<223> Description of Artificial Sequence: Primer
B1042E05

40

<400> 51
cqcqcqtatc ctattqcc

18

45 <210> 52
<211> 20
<212> DNA
<213> Artificial Sequence

50 <400> 52
qccqqaaatq ttatacctac

20

55 <210> 53
<211> 80
<212> DNA
<213> Artificial Sequence

60 <223> Description of Artificial Sequence: ICA217

<400> 53
atgaccgctt gtcataacctg ccgcaagctt aaaactcggt gcgatcttga tccacgaggg 60
catgcctgcc gcccgtgcct 80

5 <210> 54
<211> 80
<212> DNA
<213> Artificial Sequence

10 <220>
<223> Description of Artificial Sequence: ICA218

<400> 54
15 atgactgctt gccacacacctg ccgcaagctt aaaactcggt gcgatcttga tccacgaggg 60
catgcctgcc gcccgtgcct 80

INTERNATIONAL SEARCH REPORT

Inte al Application No
PCT/DK 01/00169

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C12N15/31 C12N15/67 // (C12N15/31, C12R1:69)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

EPO-Internal

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	WO 00 20596 A (NOVONORDISK AS) 13 April 2000 (2000-04-13) the whole document ---	1-50
X	DATABASE SWISS-PROT [Online] accession no. P39529, 1 November 1997 (1997-11-01) B PURNELLE ET AL: "Putative 86.7 kda transcriptional regulatory protein in NUC1-NCE1 intergenic region" XP002901831 page 45 -page 76 --- -/-	1,5,12, 14,15, 17-20,25

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

° Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "U" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the International search

Date of mailing of the International search report

2 August 2001

20.08.2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl
Fax: (+31-70) 340-3016

Authorized officer

Hampus Rystedt

INTERNATIONAL SEARCH REPORT

Int'l Application No
PCT/DK 01/00169

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DATABASE SWISS-PROT [Online] accession no P38114, 1 February 1995 (1995-02-01) ENTIAN K.-D ET AL: "Putative 126.9 kda transcriptional regulatory protein in YSW1-RIB7 intergenic region" XP002901832 page 106 -page 142 ---	1,5,12, 14,15, 17-20,25
A	WO 97 12045 A (CHIRON CORP) 3 April 1997 (1997-04-03) the whole document ---	1-50
A	WO 95 35385 A (NOVONORDISK AS) 28 December 1995 (1995-12-28) the whole document ---	1-50
A	K L PETERSEN: "A new transcriptional activator for amylase genes in <i>Aspergillus</i> " MOL GEN GENET, vol. 262, 1999, pages 668-676, XP002901833 the whole document -----	1-50

INTERNATIONAL SEARCH REPORT

Information on patent family members

Int'nal Application No

PCT/DK 01/00169

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 0020596	A 13-04-2000	AU 5850999 A		26-04-2000
		EP 1117798 A		25-07-2001
WO 9712045	A 03-04-1997	AU 7112796 A		17-04-1997
WO 9535385	A 28-12-1995	AU 2733895 A		15-01-1996
		CN 1150824 A		28-05-1997
		EP 0770139 A		02-05-1997
		FI 965031 A		16-12-1996
		JP 10501414 T		10-02-1998
		US 6025185 A		15-02-2000